Biochemistry Program
Department of Chemistry and Biochemistry
Florida State University
Tallahassee, FL 32306-4390

E-mail: qxsang@chem.fsu.edu
PHONE: (850) 644-8683
FAX: (850) 644-8281
CSL 3007

Qing-Xiang Amy SANG, Ph.D.
Professor
Endowed Professorship in Cancer Research

Ph.D. Georgetown University Medical Center, Washington D.C., 1990


Research - Selected Publications - Group members - Conference Lectures & Posters - Invited Lectures & Seminars - Honors, Awards and Other information


Left to Right (front): Daniel J. Trueblood, Dr. Suzan M. Semaan, Prof. Qing-Xiang Amy Sang, Megan E. Muroski, Dr. Zahraa I. Khamis, Holly R. Monroe

Left to Right (back): Chi Ben, Dr. Mark Druen Roycik, Dr. Ziad J. Sahab, Dr. Robert G. Newcomer, Dr. Qiang Cao, Dr. Seakwoo Lee

Left to Right: Manuel Constantino, Dr. Bin Qi, Dr. Suzan Semaan, Dale Bosco, Dr. Amy Sang, Dr. Mark Druen Roycik (back), Dr. Qiang Cao (front), Dr. Zahraa Khamis

Left to Right (front): Siyuan Xiong, Dr. Zahraa I. Kamis, Jennifer Myers, Dr. Sang

Left to Right (back): Paul Stewart, Dale Bosco, Dr. Roycik

Left to Right (front): Manny Constantino, Dr. Mark Druen Roycik, Dale Bosco, Dr. Sang, Jennifer Myers, Siyuan Xiong, Luxi Qiao

Left to Right (back): Paul Stewart, Dr. Liang Kang

Around the Table (left to right): Mark Katz, Kelsey Decker-Pulice, Dr. Mark Druen Roycik, Dale Bosco, Dr. Sang, Siyuan Xiong, Paul Stewart, Dr. Liang Kang

In the Back (left to right): Dr. Sang, Jennifer Myers, Ty C. Carzoli

Left to Right: Jennifer Myers, Dr. Mark Druen Roycik, Manny Constantino, Dale Bosco, Siyuan Xiong, Dr. Sang, Paul Stewart

Left to Right: Weixiong Xia, Dale Bosco, Dr. Amy Sang, Paul Stewart, Jennifer Myers, Dr. Mark Druen Roycik, Betul Bozdogan Pala

Left to Right: Jennifer Luks, Kaitlin Nicholson, Dr. Mark Druen Roycik, Dr. Amy Sang, Cedric Sheffield, Ty Lively, Jennifer Myers, Mark Katz, Paul Stewart, Weixiong Xia, Dale Bosco

 

Front Row, Left to Right: Mrs. Molly Barron and FSU President Dr. Eric Barron. Back Row, Left to Right: Dr. Amy Sang, Cedric Sheffield, Ty Lively, Dale Bosco, Paul Stewart, Jennifer Myers, Jennifer Luks

 


Sang Lab Major Research Interests

Biochemical, Molecular, and Pathological Mechanisms of Cancer, Stroke, Obesity, and Stem Cell Differentiation, and Cancer Biomarker and Drug Discovery

Professor Sang and her students, postdoctoral fellows, and collaborators have discovered and characterized a novel matrix metalloproteinase (endometase/matrilysin-2/MMP-26) in human cancers of endometrium, breast, and prostate. This protein is a putative cancer biomarker for human prostate, breast, and other types of carcinomas. The Sang lab is also investigating other new cancer biomarkers including phosphoproteins and glycoproteins. Furthermore, Dr. Sang lab has cloned human disintegrin and metalloproteinase 19 (adamalysin 19 or ADAM 19) gene and characterized its protein. Sang lab uncovered that matrilysin and gelatinase B have plasminogen-angiostatin converting enzyme activities. This type of biochemical research may contribute to an understanding of fundamental proteinase biochemistry and cell biology. The new knowledge may have potential applications to help patients with cancer, stroke, arthritis, diabetes, obesity, and cardiovascular diseases.

Dr. Sang's laboratory is interested in protein chemistry and enzymology of metalloproteinases and their natural and synthetic inhibitors. The biological and pathological roles of these enzymes and inhibitors are investigated in the regulation of adult mesenchymal stem cell differentiation and fate. The classical biochemistry is combined with molecular biology, cell biology, material science, medicinal chemistry, and biomedical sciences. New metalloproteinases such as human tumor-derived endometase/matrilysin-2 (matrix metalloproteinase–26) and protease inhibitors such as tissue inhibitor of metalloproteinase-4 are under investigation, including cDNA cloning, protein expression, isolation, purification, characterization, sequencing, and chemical modifications. The research team is focusing on the studies of the biochemical mechanisms of zymogen activation, substrate specificities, the inhibition kinetics, and the structure-function relationships of the proteinases and their inhibitors. These synthetic small molecular enzyme inhibitors may be further developed to become potential candidates for therapeutics for treating cancer invasion, metastasis, stroke, and obesity.

Sang research team is exploring the biochemical basis and molecular mechanisms of human cancer cell progression, invasion, and metastasis. Matrix metalloproteinases (MMPs or matrixins) are a family of endopeptidases that require zinc for catalysis and calcium for protein folding. Because of their abilities to dissolve connective tissue barrier proteins such as collagens, fibronectin, and laminins, matrixins are one of the most important classes of molecules used by invading cells to facilitate invasive growth and spread. Angiogenesis, the process of new blood vessel formation, is essential for providing oxygen and nutrients for tumor growth and for generating a gateway for cancer cell metastasis. Inhibition of angiogenesis will starve tumors, induce cancer regression, and prevent the spread of cancer cells. Dr. Sang and her associates and collaborators are performing experiments to gain an understanding of the biochemical steps involved in metastasis and to develop new strategies to prevent tumor growth and to inhibit cancer angiogenesis and metastasis. Inhibition of angiogenesis may also starve fat cells and restrict fat tissue growth, thus, preventing and reducing obesity.

Dr. Sang’s “Putative Cancer Biomarker” Presentation for Dr. and Sir. Harry Kroto’s Global Educational Outreach for Science, Engineering and Technology (GEOSET) at Florida State University: http://mediasite.apps.fsu.edu/Mediasite/SilverlightPlayer/Default.aspx?peid=20956a6d47004609829ffc17a509222c1d

 

Back to the top

Publications

(*Sang as the senior corresponding author; both Q.-X. Sang and Q.A. Sang for citations)

1. 1. Q.-X. Sang, M. Dym, and S.W. Byers (1990) Secreted metalloproteinases in testicular cells in culture, Biol.Reprod. 43, 946 955

2. Q.-X. Sang, W.G. Stetler Stevenson, L.A. Liotta, and S.W. Byers (1990) Identification of type IV collagenase in rat testicular cell culture: influence of peritubular Sertoli cell interactions, Biol.Reprod. 43, 956 964

3. Q.-X. Sang, E.W. Thompson, D. Grant, W.G. Stetler Stevenson, and S.W. Byers (1991) Soluble laminin and arginine glycine aspartic acid containing peptides differentially regulate type IV collagenase messenger RNA, activation and localization in testicular cell culture, Biol. Reprod., 45, 387 394

4. Q.-X. Sang, M. Dym, and S.W. Byers (1992) Proteases in seminiferous epithelium remodeling,  Matrix, supplement, 1, 404-405

5. S. Netzel-Arnett, Q.-X. Sang, W.G.I. Moore, M. Navre, H. Birkedal-Hansen, and H.E. Van Wart (1993) Comparative sequence specificities of human 72 and 92 kDa gelatinases (type IV collagenases) and PUMP (matrilysin), Biochemistry, 32, 6427-6432

6. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Proteolytic and non-proteolytic activation of human neutrophil progelatinase, Biochim. Biophy. Acta, 1251, 99-108

7. Q.A. Sang* (1995) Specific proteolysis of ceruloplasmin by leukocyte elastase, Biochem. Mol. Biol. Int. 37, 573-581

8. Q.A. Sang* and D.A. Douglas (1996) Computational sequence analysis of matrix metalloproteinases, J. Protein Chem. 15, 137-160

9. Q.A. Sang*, M.K. Bodden, and L.J. Windsor (1996) Activation of human progelatinase A by collagenase and matrilysin; activation of procollagenase by matrilysin, J. Protein Chem.  15, 243-253

10. M.A. Stolow, D.D. Bauzon, J. Li, T. Sedgwick, V.C.-T. Liang, Q.A. Sang, and Y.-B. Shi (1996)  Identification and characterization of a novel collagenase in Xenopus laevis:  Possible roles during frog development, Mol. Biol. Cell, 7, 1471-1483.

11.  H.E. Zhau, S.-M. Chang, B.-Q. Chen, Y. Wang, H. Zhang, C. Kao,  Q.A. Sang, S.J. Pathaks, and L.W.K. Chung (1996)  Androgen-repressed phenotype in human prostate cancer, Proc. Natl. Acad. Sci. USA, 93, 15152-15157.

12. D.A. Douglas, Y.E. Shi, and Q.A. Sang* (1997) Computational sequence analysis of the tissue inhibitor of metalloproteinase family, Minireview, J. Protein Chem.  16, 237-255. 

13. C.-Y. Lin, J.-K. Wang, J. Torri, L. Dou, Q.A. Sang, and R.B. Dickson (1997) Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells: monoclonal antibody production, isolation, and localization, J. Biol. Chem. 272, 9147-9152. 

14. Y. E. Liu, M. Wang, J. Greene, J. Su, S. Ullrich, H. Li, S. Sheng, P. Alexander, Q.A. Sang, and Y.E. Shi (1997) Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4), J. Biol. Chem. 272, 20479-20483.

15. B.C. Patterson and Q.A. Sang* (1997) Angiostatin converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9),  J. Biol. Chem., 272, 28823-28825.

16. H. Li, D.D. Bauzon, X. Xu, H. Tschesche, J. Cao, and Q.A. Sang* (1998) Immunological characterization of cell surface and soluble forms of membrane-type 1 matrix metalloproteinase in human breast cancer cells and fibroblasts,  Molecular  Carcinogenesis, 22, 84-94.

17. Q.X. Sang* (1998) Complex role of matrix metalloproteinases in angiogenesis.  Minireview.  Cell Res.  8, 171-177. 

18. C.M. Dollery, J.R. McEwan, M. Wang, Q.A. Sang, Y.E. Liu, Y. Eric Shi (1999) TIMP-4 is regulated by vascular injury in rats.  Circulation Research 84, 498-504. 

19. G. Xiao, Y.E. Liu, R. Gentz, Q.A. Sang, J. Ni, I.D. Goldberg, Y.E. Shi (1999) Suppression of breast cancer growth and metastasis by a novel serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.   Proc. Natl. Acad. Sci. USA.  96, 3700-3705.

20. A.L. Stone, M. Kroeger, and Q.X. Sang* (1999) Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase containing proteins.  Review.  J. Protein Chem. 18, 447-465. 

21. C.-Y. Lin, J. Anders, M. Johnson, Q.A. Sang, and R.B. Dickson (1999)  Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity.  J. Biol. Chem. 274, 18231-18236. 

22. S.C. Mueller, G. Ghersi, S.K. Akiyama, Q.-X. Sang, L. Howard, M. Pineiro-Sanchez, H. Nakahara, Y. Yeh, and W.-T. Chen (1999)  A novel protease-docking function of integrin at invadopodia.   J. Biol. Chem.  274, 24947-24952.  

23. Q.-X. Sang*, M.-C. Jia, M.A. Schwartz, M.C. Jaye, H.K. Kleinman, M.A. Ghaffari, and Y.-L. Luo (2000) New thiol and sulfodiimine metalloproteinase inhibitors and their effect on human microvascular endothelial cell growth. Biochem. Biophys. Res. Commun.  274, 780-786.

24. M.-C. Jia, M. A. Schwartz, and Q.A. Sang* (2000) Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors, Targeting angiogenesis with MMP inhibitors.  Adv. Exp. Med. Biol. 476, 181-194.

25. S. Hernandez-Barrantes, M. Toth, M.M. Bernardo, M. Yurkova, D.C. Gervasi, Y. Raz, Q.A. Sang, R. Fridman (2000) Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation.  J. Biol. Chem.  275, 12080-12089.  

26. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang* (2000) Identification and Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial Tumor. J. Biol. Chem.  275, 20540-20544.

27.   P. Wei, Y.-G. Zhao, L. Zhuang, S. Ruben, and Q.-X. Sang* (2001) Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta.  Biochem. Biophys. Res. Commun.  280, 744-755

28. Hurst, D. R., Li, H., Xu, X., Badisa, V. L., Shi, Y. E., and Sang, Q.-X.* (2001).  Development and characterization of a new polyclonal antibody specifically against tissue inhibitor of metalloproteinases 4 (TIMP-4) in human breast cancer.  Biochem. Biophys. Res. Commun.  281, 166-171. 

29. Y. Jiang, M. Wang, M.Y. Celiker, Q.-X. Sang, Y.E. Liu, I.D. Goldberg, and Y.E. Shi (2001). Stimulation of mammary tumorigenesis by systemic tissue inhibitors of matrix metalloproteinase 4 gene delivery. Cancer Res. 61, 2365-2370. 

30. S. Hernandez-Barrantes, Y. Shimura, P.D. Soloway, Q.A. Sang, and R. Fridman (2001) Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP.  Biochem. Biophys. Res. Commun.  281, 126-130. 

31. Y.-G. Zhao, P. Wei, and Q.-X. Sang* (2001) Inhibitory Antibodies against Endopeptidase Activity of Human Adamalysin 19.  Biochem. Biophys. Res. Commun.  289, 288-294. 

32. J. Zhang, Y.-J. Cao, Y.-G. Zhao, Q.-X. Sang, and E.-K. Duan (2002) Expression of matrix metalloproteinase-26 and tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast cells and a choriocarcinoma cell line, JEG-3. Mol. Human Reprod. 8, 659-666.

33. P. Wei, Y.-G. Zhao, L. Zhuang, D.R. Hurst, S. Ruben, and Q.-X. Sang* (2002) Protein Engineering and Properties of Human Metalloproteinase and Thrombospondin 1.  Biochem. Biophys. Res. Commun.  293, 478-488.

34. T.-B. Kang, Y.-G. Zhao, D. Pei, J.F. Sucic, and Q.-X. Sang* (2002) Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites.  J. Biol. Chem. 277, 25583-25591. 

35. Li, Q., Wang, H., Zhao, Y., Lin, H., Sang, Q.A., Zhu, C. (2002) Identification and specific expression of matrix metalloproteinase-26 in rhesus monkey endometrium during early pregnancy. Mol. Hum. Reprod. 8, 934-940. 

36. H.I. Park, B.E. Turk, F.E. Gerkema, L.C. Cantley, and Q.-X. Sang* (2002) Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26.  J. Biol. Chem.  277, 35168-35175. 

37. T. Kang, H. I., Park, Y. Suh, Y.-G. Zhao, H. Tschesche, and Q.-X. Sang* (2002) Autolytic Processing at Glu(586)-Ser(587) within the Cysteine-rich Domain of Human Adamalysin 19/Disintegrin-metalloproteinase 19 is Necessary for its Proteolytic Activity.  J. Biol. Chem. 277, 48514-48522.

38. J. Zhang, Y.-G. Zhao, Y.-J. Cao, Q.-X. Sang, and E.-K. Duan (2003) Expression and implications of tissue inhibitor of metalloproteinases-4 in mouse embryo. Mol. Hum. Reprod. 9, 143-149.

39. X. Liao, J.B. Thrasher, J. Pelling, J. Holzbeierlein, Q.-X. Sang, and B. Li (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer.  Endocrinology. 144, 1656-1663.

40. Y.-G. Zhao, A. Xiao, R.G. Newcomer, H.I. Park, T. Kang, L.W.K. Chung, M.G. Swanson, H. E. Zhau, J. Kurhanewicz,  and Q.-X. Sang* (2003) Activation of Pro-Gelatinase B by Endometase/Matrilysin-2 Promotes Invasion of Human Prostate Cancer Cells.  J. Biol. Chem. 278, 15056-15064.

41. R. Tunuguntla, D. Ripley, Q.-X. Sang, and N. Chegini (2003) Expression of Matrix Metalloproteinase-26 and Tissue Inhibitors of Metalloproteinases TIMP-3 and –4 in Benign Endometrium and Endometrial Cancer. Gynecol. Oncol.  89, 453-459.

42. H.I. Park, Y. Jin, D.R. Hurst, C.A. Monroe, S. Lee, M.A. Schwartz, and Q.-X. Sang* (2003) The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem., 278:51646-51653.

43. D. R. Hurst, M.A. Schwartz, M.A. Ghaffari, Y. Jin, H. Tschesche, G.B. Fields, and Q.-X. Sang*  (2004)  Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem. J. 377, 775-779.

44. Y.-G. Zhao, A.-Z. Xiao, H.I. Park, R.G. Newcomer, M. Yan, Y.-G. Man, S.C. Heffelfinger, and Q.-X. Sang* (2004) Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4:  a putative role in the initiation of breast cancer invasion.  Cancer Res. 64, 590-598.

45. T. Kang, H. Tschesche, and Q.-X. Sang* (2004) Evidence for Disulfide Involvement in the Regulation of Intramolecular Autolytic Processing by Human Adamalysin19/ADAM19. Exp. Cell Res. 298, 285-295.

46. Y.-G. Man* and Q.-X. Sang* (2004) The Significance of Focal Myoepithelial Cell Layer Disruptions in Human Breast Tumor Invasion: a Paradigm Shift from the “Protease-centered” Hypothesis. Exp. Cell Res. 301, 103-118.

47. W. Qiu, L. Zhao, S.-X. Bai, Q.-X. Sang, Y.-L. Wang (2005) Expression of matrix metalloproteinase-26 in human normal placental cytotrophoblast cells as well as its regulation by activin A. Prog. Biochem. Biophys. 32, 25-30.

48. W. Qiu, S.-X. Bai, M.-R. Zhao, X.-Q. Wu, Y.-G. Zhao, Q.-X. Sang, Y.-L. Wang (2005) Spatio-temporal expression of matrix metalloproteinase-26 in human placental trophoblasts and fetal red cells during normal placentation. Biol. Reprod. 72, 954-959. Epub 2004 Dec 15.

49. Y.-G. Man, T. Shen, Y.-G. Zhao, and Q.-X. Sang (2005) Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect. Prev. 29, 161-169.

50. H.-X. Wang, Y.-G. Zhao, H.M. Wang, Q. Yang, H.-Y. Lin, Q.-X. Sang, C. Zhu (2005) Expression of adamalysin 19/ADAM19 in the endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy.  Mol Hum Reprod. 11, 429-435. Epub 2005 May 18.

51. D.R. Hurst, M.A. Schwartz,Y. Jin, M.A. Ghaffari, P. Kozarekar, J. Cao, Q.-X. Sang* (2005) Inhibition of enzyme activity and cell-mediated substrate cleavage of membrane type 1-matrix metalloproteinase by newly developed mercaptosulfide inhibitors. Biochem. J. 392, 527-536. Epub 2005 Jul 19.

52. Y.-G. Man, T. Shen, J. Weisz, P.E. Berg, A.M. Schwartz, J.L. Mulshine, Q.-X. Sang, and H.E. Nieburgs (2005) A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect. Prev. 29, 323-331. Epub 2005 Aug. 22.

53. Z.J. Sahab, Y. Suh, and Q.-X. Sang* (2005) Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis. J. Proteome Res. 4, 2266-2272. Epub 2005 Nov. 18. DOI: 10.1021/pr0501822.

54. Q.-X. Sang*, Y. Jin, R.G. Newcomer, S.C. Monroe, X. Fang, D.R. Hurst, S. Lee, Q. Cao, and M.A. Schwartz (2006) Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases. Current Topics in Medicinal Chemistry. 6, 289-316. Invited review.

55. Q. Yang, H.X. Wang, Y.G. Zhao, H.Y. Lin, H. Zhang, H.M. Wang, Q.X. Sang, C. Zhu. (2006) Expression of tissue inhibitor of metalloproteinase-4 (TIMP-4) in endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy. Life Sci. 78, 2804-2811. 2005 Dec 20; [Epub ahead of print]

56. S. Bu, C. Cao, Y. Yang, C. Miao, Z. Hu, Y. Cao, Q. A. Sang, and E. Duan (2006) Localization and temporal regulation of tissue inhibitor of metalloproteinases-4 in mouse ovary. Reproduction. 131, 1099-1107.

57. D. Wildeboer, S. Naus, Q.-X. Sang, J.W. Bartsch, and A. Pagenstecher (2006) Metalloproteinase-disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol. 65, 516-527.

58. S. Lee, K. K. Desai, K.A. Iczkowski, R.G. Newcomer, K.J. Wu, Y.-G. Zhao, W.W. Tan, M.D. Roycik, and Q.-X. Sang* (2006) Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 16, 750-758.

59. S.-M. Bu, Y.-J. Yang, C.-L. Miao, H.-J. Li, R.G. Newcomer, Q.-X. Sang, E.-K. Duan (2006) Developmental and hormonal regulation of meltrin beta (ADAM19) expression in mouse testes during embryonic and postnatal life. Life Sci. 79, 2112-2118. Epub 2006 Jul 12.

60. Z.J. Sahab, S.M. Semaan, and Q.-X. Sang* (2007) Methodology and Applications of Disease Biomarker Identification in Human Serum. Invited Review. Biomarker Insights. 2, 21-43.

61. S. Lee, H.I. Park, and Q.-X. Sang* (2007) Calcium Regulates Tertiary Structure and Enzymatic Activity of Human Endometase/Matrilysin-2 and its Role in Promoting Human Breast Cancer Cell Invasion.  Biochem. J. 403, 31-42.

62. J. Hu, P.E. Van den Steen, Q.-X. Sang, and G. Opdenakker (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews Drug Discovery. 6, 480-498. Invited review.

63.  Z.J. Sahab, K. Iczkowski, and Q.-X. Sang* (2007) Anion Exchange Fractionation of Serum Proteins versus Albumin Elimination.  Anal. Biochem. 368, 24-32.

64. M.E. Muroski, M.D. Roycik, R.G. Newcomer, P.E. Van den Steen, G. Opdenakker, H.R. Monroe, Z.J. Sahab, and Q.-X. Sang* (2008) Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis. Current Pharmaceutical Biotechnology 9, 34-46. Invited Review.

65. Y. Zhao, C.E. Lyons Jr.; A. Xiao, D.J. Templeton, Q.A. Sang, K. Brew, I.M. Hussaini (2008) Urokinase directly activates matrix metalloproteinase-9: A potential role in glioblastoma invasion. Biochem. Biophys. Res. Commun. 369, 1215-1220.

66. M.D. Roycik, X. Fang, and Q.-X. Sang* (2009) A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr. Pharmaceutical Design, 15, 1295-1308. Invited Review.

67. B. Qi, R.G. Newcomer, and Q.-X. Sang* (2009) ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases. Current Pharmaceutical Design, 15, 2336-2348. Invited Review.

68. W.-Y. Yang, B. Breiner, S.V. Kovalenko, C. Ben, M. Singh, S.N. LeGrand, Q.-X. Sang, G.F. Strouse, J.A. Copland, I.V. Alabugin (2009) C-Lysine Conjugates: pH-Controlled Light-Activated Reagents for Efficient Double Stranded DNA Cleavage with Implications for Cancer Therapy. J. Am. Chem. Soc. 131,11458-11470.

69. M. Zhao, W. Qiu, Y. Li, Q.A. Sang, and Y. Wang (2009) Dynamic change of Adamalysin 19 (ADAM19) in human placentas and its effects on cell invasion and adhesion in human trophoblastic cells. Sci. China C Life Sci. 52, 710-718.

70. Y.-G. Zhao, A.-Z. Xiao, J. Ni, Y.-G. Man, and Q.-X. Sang* (2009) Elevated Expression of Matrix Metalloproteinase-26 in Multiple Human Cancer Tissues and Expression in Smooth Muscle Cells. Ai Zheng (Chinese J. Cancer), 28, 1168-1175.

71. H.I. Park, S. Lee, A. Ullah, Q. Cao, and Q.-X. Sang* (2010) Effects of Detergents on Catalytic Activity of Human Endometase/Matrilysin-2, a Putative Cancer Biomarker. Anal. Biochem. 396, 262-268.

72. Z. J. Sahab, Y.-G. Man, S. M. Semaan, R.G. Newcomer, S.W. Byers, and Q.-X. A. Sang* (2010) Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype. Clin. Exp. Metastasis. 27, 493-503.

73. Z.I. Khamis, K.A. Iczkowski, Z.J. Sahab, and Q.X. Sang* (2010) Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues. J. Cancer. 1, 70-79.

74. W.Y. Yang, Q. Cao, C. Callahan, C. Galvis, Q.-X. Sang, and I.V. Alabugin (2010) Intracellular DNA damage by lysine-acetylene conjugates.J. Nucleic Acids. 2010 Aug 9;2010. pii: 931394.PMID: 20814583.

75. R.G. Newcomer, M.D. Moussallem, T.C.S. Keller, J.B. Schlenoff, and Q.-X. Sang* (2011) Divergent Human Vascular Smooth Muscle Cell Response to Polyelectrolyte Multilayer Bio-Interfaces. Biotechnol. Res. Int. Vol. 2011, Article ID 854068. doi:10.4061/2011/854068.  

76. S.M. Semaan and Q.-X. Sang (2011) Prefractionation enhances loading capacity and identification of basic proteins from human breast cancer tissues.

Anal. Biochem. 411, 80-87.  2010 Dec 10. [Epub ahead of print] PMID: 21146488.  doi:10.1016/j.ab.2010.12.010.

77. S. Lee, D. Terry, D. R. Hurst, D.R. Welch, and Q.-X. Sang* (2011) Protein Signatures in Human MDA-MB-231 Breast Cancer Cells Indicating a More Invasive Phenotype Following Knockdown of Human Endometase/Matrilysin-2 by siRNA. J. Cancer. 2, 165-176.

78. D. Min, M. Chen, L. Zheng, Y. Jin, M.A. Schwartz, Q.X. Sang, W. Yang (2011)  Enhancing QM/MM Molecular Dynamics Sampling in Explicit Environments via an Orthogonal-Space-Random-Walk-Based Strategy. J. Phys. Chem. B. 115, 3924-3935. Epub 2011 Mar 21.

79. S.M. Semaan, X. Wang, P.A. Stewart, A.G. Marshall, and Q.-X. Sang* (2011) Differential Phosphopeptide Expression in a Benign Breast Tissue, and Triple-Negative Primary and Metastatic Breast Cancer Tissues from the Same African-American Women by LC-LTQ/FT-ICR Mass Spectrometry.  Biochem. Biophy. Res. Comm. 412, 127-131. Epub 2011 Jul 23.

80. Z.J. Sahab, Y.-G. Man, S.W. Byers, Q.-X. Sang (2011) Putative Biomarkers and Targets of Estrogen Receptor Negative Human Breast Cancer. Int. J. Mol. Sci. 12, 4504-4521. Invited review.

81. X. Wang, P.A. Stewart, Q. Cao, Q.-X. Sang, L.W.K. Chung, M.R. Emmett, A.G. Marshall (2011) Characterization of the Phosphoproteome in Androgen-Repressed Human Prostate Cancer Cells by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. J. Proteome Res. 10, 3920-3928.  Epub 2011 Jul 26.

82. Y. Yang, F.Y. Jalal, J.F. Thompson, E.J. Walker, E. Candelario-Jalil, L. Li, R.R.  Reichard, C. Ben, Q.-X. Sang, L.A.A. Cunningham, and G.A. Rosenberg. Tissue Inhibitor of Metalloproteinases-3 Mediates the Death of Immature Oligodendrocytes via TNF-alpha/TACE in Focal Cerebral Ischemia in Mice (2011) J. Neuroinflammation  2011 Aug. 29; 8(1): 108. Epub ahead of print.

83. M.L. Moss, G. Powell, M.A. Miller, L. Edwards, B. Qi, Q.-X. Sang, B. De Strooper, I. Tesseur, S.F. Lichtenthaler, M.Taverna, J.L. Zhong, C. Dingwall, T. Ferdous, U. Schlomann, P. Zhou , L.G. Griffith, D.A. Lauffenberger, R. Petrovich, and J.W. Bartsch (2011) ADAM9 inhibition increases membrane activity of ADAM10 and controls alpha-secretase processing of amyloid precursor protein. J. Biol. Chem. 286,40443-40451.

84. Z.I. Khamis, Z.J. Sahab, S.W. Byers, and Q.-X. Sang* (2011) Novel Stromal Biomarkers in Human Breast Cancer Tissues Provide Evidence for the More Malignant Phenotype of Estrogen Receptor Negative Tumors. J. Biomed. Biotechnol. 2011:723650. Epub 2011 Oct. 3, 2011.

85. Q.-X. Sang, Y.-G. Man, Y.M. Sung, Z.I. Khamis, L. Zhang, M.-H. Lee, S.W. Byers, and Z.J. Sahab (2012) Non-receptor Tyrosine Kinase 2 Reaches its Lowest Expression Levels in Human Breast Cancer during Regional Nodal Metastasis. Clin. Exp. Metastasis. 29, 143-153. 2011 Nov 25, Epub ahead of print.

86. Z.I. Khamis, Z. J. Sahab, and Q.-X. Sang* (2012) Active roles of tumor stroma in breast cancer metastasis. Int. J. Breast Cancer, vol. 2012, Article ID 574025, 10 pages, 2012, doi:10.1155/2012/574025.87. Z.I. Khamis, Z. J. Sahab, and Q.-X. Sang* (2012) Active roles of tumor stroma in breast cancer metastasis. Int. J. Breast Cancer, vol. 2012, Article ID 574025, 10 pages, 2012, doi:10.1155/2012/574025.

87. Z.I. Khamis, K.A. Iczkowski, Q.-X. Sang* (2012) Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med. Res. Rev. 32, 1026-1077. doi: 10.1002/med.20232. Epub 2011 Jan 16.

88. S.A. Krieg, X. Fan, Y. Hong, Q-X.  Sang, A.Giaccia, L.M. Westphal,  R.B. Lathi, A.J. Krieg, and N.R. Nayak (2012) Global alteration in gene expression profiles of deciduas from women with idiopathic recurrent pregnancy loss.  Mol. Hum. Reprod. 18, 442-450. Epub ahead of print. 2012 May 4.

89. S.M. Semaan, X. Wang, A.G. Marshall, Q.-X. Sang* (2012) Identification of Potential Glycoprotein Biomarkers in Estrogen Receptor Positive (ER+) and Negative (ER-) Human Breast Cancer Tissues by LC-LTQ/FT-ICR Mass Spectrometry. J. Cancer. 3, 269-284. Epub 2012 Jun 21.

90. S.M. Semaan, Z. Wang, M.D. Roycik, X. Fang, and Q.X.A. Sang* (2013) MMP26 (matrix metallopeptidase 26). Review. Atlas Genet. Cytogenet. Oncol. Haematol. 17(2): 110-114.

91. Z.I. Khamis, D.A.R. Zorio*, L.W.K. Chung, and Q.-X. Sang* (2013) The anti-inflammatory role of endometase/matrilysin-2 in human prostate cancer cells, J. Cancer. 4(4): 296-303. doi:10.7150/jca.5788.

92. M.D. Roycik, J.S. Myers, R.G. Newcomer, and Q.-X. Sang* (2012) Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke. Curr Mol Med. 2013 Sep;13(8):1299-313.

93. Y. Jin, M.D. Roycik, D.B. Bosco, Q. Cao, M.H. Constantino, M.A. Schwartz, and Q.-X. Sang* (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73. doi: 10.1021/jm400529f. Epub 2013 May 16.

94. Mu T, Liang W, Ju Y, Wang Z, Wang Z, Roycik MD, Sang QX, Yu D, Xiang H, Fang X. Efficient soluble expression of secreted matrix metalloproteinase 26 in Brevibacillus choshinensis. Protein Expr Purif. 2013 Oct;91(2):125-33. doi: 10.1016/j.pep.2013.07.012. Epub 2013 Aug 3.

95. Stewart PA, Luks J, Roycik MD, Sang QX, Zhang J. Differentially expressed transcripts and dysregulated signaling pathways and networks in african american breast cancer. PLoS One. 2013 Dec 4;8(12):e82460. doi: 10.1371/journal.pone.0082460.

 

   



Book Chapters and Conference Papers

(Sang as the senior corresponding author; both Q.-X. Sang and Q.A. Sang for citations)

Y.-B. Shi and Q.A. Sang (1998) 392. Collagenase 4.  In Handbook of Proteolytic Enzymes. Editors:  A.J. Barrett, N.D. Rawlings, and J.F. Woessner.  Academic Press, Orlando, Florida. pp. 1170-1172.

Q.A. Sang*, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau (1999) Targeting matrix metalloproteinases in human prostate cancer.  Ann. N.Y. Acad. Sci. 878, 538-540.

C.M. Dollery, J.R. McEwan, M. Wang, Q.A. Sang, Y.E. Liu, and Y.E. Shi (1999)  TIMP 4 is regulated by vascular injury in rats.  Ann. N.Y. Acad. Sci. 878, 740 741.

Q.X. Sang* and Y.-B. Shi* (2004) Collagenase 4.  In Handbook of Proteolytic Enzymes. Chapter 128. 2nd edition.  Editors:  A.J. Barrett, N.D. Rawlings, and J.F. Woessner.  Elsevier Academic Press, London, San Diego. pp. 494-497.  

Q.X. Sang* (2004) Matrilysin-2.  In Handbook of Proteolytic Enzymes. Chapter 135.  2nd edition.  Editors:  A.J. Barrett, N.D. Rawlings, and J.F. Woessner.  Elsevier Academic Press, London, San Diego. pp. 538-540.

T. Kang, R.G. Newcomer, Y.-G. Zhao, and Q.-X. Sang* (2005) Chapter 9: ADAM19: Domain structure, regulation, processing and functions. “The ADAMs Family of Proteases”. In the Proteases in Biology and Disease series. Vol. 4. Editors: N.M. Hooper and U. Lendeckel.  Springer, The Netherlands, pp.199-221.

Q.X. Sang* (2012) Matrix Metalloproteinase-26/Matrilysin-2. In Handbook of Proteolytic Enzymes. Chapter M661.  3rd edition.  Editors:  N.D. Rawlings and Guy Salvesen.  Elsevier Academic Press, London, San Diego. Published.


Back to the top


Undergraduate Students, Graduate Students, Postdoctoral and other Research Assistants/Associates Trained in Dr. Sang’s Lab

                   Graduate Students:

                   Graduate and Undergraduate Students and Postdoctoral and other Research Assistants/Associates Trained at Professor Sang’s Lab (Sang as the Major Professor/Mentor)

                   Nine (9) Ph.D. students graduated (Dr. Sang as the Major Professor)

                   Douglas R. Hurst, Summer 99- Dec. 2003.   Graduated with his Ph.D. degree in Biochemistry, Dec. 2003.  Dissertation title:  “Inhibition of membrane type 1-matrix metalloproteinase with mercaptosulfide inhibitors”. Hurst is one of the winners of Russell and Dorothy Johnsen Dissertation Award for the Outstanding Graduate Student, 2003-2004. Current position: Assistant Professor, Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, Alabama. 2011-

Ziad J. Sahab, Summer 2003-Dec. 2005. Graduated with his Ph.D. degree in Bio-analytical Chemistry, Dec. 2005.  Dissertation title:  Batch anion exchange separation: a prefractionation technique for proteome research and its applications on in vivo cancer samples. Current position:  Assistant Professor at the Department of Oncology, Georgetown University Lombardi Cancer Center in Washington D.C. 2011-.

Yewseok Suh, Aug. 2000-July 2006.  Graduated with his Ph.D. degree in Biochemistry, Aug. 2006. Dissertation title:   Molecular characterization of tea catechin-treated human prostate cancer cell lines. Current position:  Postdoctoral Research Associate, University of Wisconsin, Madison, Wisconsin. 2006-

Seakwoo Lee, Spring 2001-August 2007.  Graduated with his Ph.D. degree in Biochemistry, Aug. 2007.  Dissertation title:  Calcium Dependency of Human Matrix Metalloproteinase-26 and its Potential Contribution to Early-stage Adenocarcinoma. Current position:  Postdoctoral Research Associate, Johns Hopkins University, Baltimore, Maryland. 2007-

                        Robert G. Newcomer, Spring 2002-Summer 2007. Graduated with his Ph.D. degree in Biochemistry, Dec. 2007.  Dissertation title: The Influence of Adamalysin 19 and Polyelectrolyte Multilayers on Human Vascular Smooth Muscle Cells.Current position:  Scientific and Medical Writer. Upside Endeavors, LLC, Sanatoga, Pennsylvania. 2007-

Mark Druen Roycik, Summer 2004-Summer 2010. Biochemistry. Graduated with his Ph.D. degree in Biochemistry, August 2010.  Dissertation title: Mercaptosulfonamides: Potential “switches” of Human Mesenchymal Stem Cell Behavior. Current position:  Postdoctoral Research Associate and Laboratory Manager, Florida State University.

Qiang Cao, Summer 2003-Fall 2010. Biochemistry. Graduated with his Ph.D. degree in Biochemistry, December 2010.  Dissertation title: Biochemical Characterization of Human Matrix Metalloproteinases and Their Newly Designed Inhibitors Related to Stroke. Current position:  Postdoctoral Research Associate, The Wistar Institute, University of Pennsylvania, Philadelphia, PA, USA.

Zahraa I. Khamis, Spring 2007-Spring 2011. Biochemistry. Passed dissertation defense on February 21, 2011. Graduated with her Ph.D. degree in Biochemistry, April 29, 2011. Dissertation title: Putative Protein Biomarkers in Human Breast and Prostate Cancer Tissues and Implication of Endometase/Matrilysin-2 in Inflammation and Apoptosis. Current Position: Postdoctoral Research Associate and Instructor, Lebanese University, Beirut, Lebanon.

                        Suzan Marie Semaan, Spring 2006-Spring 2011. Biochemistry. Passed Ph.D. Dissertation defense on March 23, 2011. Graduated with her Ph.D. degree in Biochemistry, April 29, 2011.  Dissertation title: Proteomics of Putative Protein Biomarkers in Human Breast Cancer Tissues. Current Position:  Postdoctoral Research Associate, Saint Joseph Hospital and Research Center, Phoenix, AZ, USA.

 

 

                        Master’s students graduated: six (6)

                        Anne L. Stone, Summer 98-Summer 99.  M.S. degree. Biochemistry, Summer 99.

                        Vladimir E. Belozerov, Fall 98-Spring 99. M.S.  degree. Biochemistry, Summer 99.

                        Elena Filenova, Fall 2000-Summer 2002.  M.S. degree. Biochemistry, Summer 02.

                        Daniel J. Trueblood, Summer 2005-Spring 2007. M.S. degree. Biochemistry, Spring 2007.

                        Chi Ben, Spring 2006-Summer 2009. M.S. degree. Biochemistry, Summer 2009.

Siyuan Xiong, Fall 2010-Summer 2012. M.S. degree. Biochemistry, Summer 2012. She is a Ph.D. graduate student at the University of British Columbia, Vancouver, Canada in spring 2013.

                        Current Graduate Students (Dr. Sang as the Major Professor)

                        Current number of doctoral students: Four (4)

Paul Stewart, Fall 2009-present. Biochemistry.

Dale B. Bosco, Summer 2010-present. Molecular Biophysics.

Jennifer S. Myers, Spring 2011-present. Analytical Chemistry.

Karin A. Vallega, Fall 2013 – present. Biochemistry.

                        Graduate Students Did Lab Rotations at Dr. Sang’s Lab

Delbert D. Bauzon, Fall 95-Summer 97.  M.S. Biochemistry. Summer 95.

Paul H. Schmid, Spring 96-Fall 1997.    Biochemistry

Brian C. Patterson, Spring 96-Fall 96.  Biochemistry

Shawn A. Clark, Summer 98-Spring 99.   Biochemistry

Andrew A. Korostelev, Fall 98.  Biochemistry

Laura A. Mertz, Fall 98.  Biochemistry

Cheri Bunder, Fall 98.  Biochemistry

Bradley D. Prater, Fall 98-Summer 99.  Biochemistry

Fuli Yu, Spring 99-summer 2000. Biochemistry

Jeff Bush, Spring 2000. Biochemistry

Georgia A. Wilkie, Summer 2000. Fall 2000. Biochemistry

Jocelyn Dudley, Summer 2001.  Biochemistry.

Gurunathan Laxmikanthan, Fall 2001.  Biochemistry.

Brent Ginn, Fall 2001.  Biochemistry.

Qiao Ren, Spring 2002. Biochemistry.

Faqing Yuan, Summer 2002. Biochemistry.

Joycelynn D. Nelson, Spring 2003. Biochemistry.

Mitesh Jivan, Fall 2002-Spring 2003. Biochemistry.

Jacqueline Kitchen, Fall 2003. Molecular Biophysics

Jared Pikus, Fall 2003. Molecular Biophysics

Augustine Felix, Spring 2005. Biochemistry

Cristina D. Russo, Spring 2005. Molecular Biophysics

Kevin K. Desai, Summer 2005. Biochemistry

Huimin Zhang, Fall 2005. Molecular Biophysics

Dale Bosco, Summer-Fall 2009. Molecular Biophysics

Carol Porter, Fall 2009, Biochemistry

Joey Bowler, Fall 2009, Biochemistry

Paul Stewart, Fall 2009, Biochemistry

Anna Kozlova, Fall 2009. Molecular Biophysics

Siyuan Xiong, Fall 2010. Biochemistry.

Anna Kozlova, Fall 2009. Molecular Biophysics

Manuel H. Constantino, Summer 2009-Spring 2012. Biochemistry.

Siyuan Xiong, Fall 2010. Biochemistry

Rebecca Beasley, Yara Ghoussoub, Trevor Harris, Parth Vakil, Katelyn Fredrickson, Matthew Dickman, Teresa Eaton, and Alan Shomo, Fall 2012, Chemistry & Biochemistry, lab exploration

                        Undergraduate Research Students (Sang as the Major Professor/Mentor):

Annette Vaughan, CHM 1051L, Spring 93.

Damon A. Douglas, Student Assistant, Fall 94-Summer 96.

Rachel K. Stilwell, CHM 4905, DIS, Spring 95.

Scott A. Gass, CHM 4905, DIS, Spring 95.

Michael B. Dillhyon, CHM 4905, DIS, Summer 95.

Ian Davis, CHM 1051L, Spring 96.

Mayra Martin, CHM 4905, Spring 96; CHM 3930r, Fall 96; Student Assistant, Spring-Summer 97.

James Mike Magill, CHM 3930r, Fall 96-Spring 97; Student Assistant, Summer 97-Spring 98, Fall 98-Spring 99.

Edwin Alex Melendez, CHM 3930r, Fall 96-Spring 98; FSU UMRTP-NSF Award recipient.

Nneka Lotea Ifejika, FSU UMRTP-NSF Award recipient.  Spring 97.

T. Noelle Lombana, CHM 1051L, Spring 97; CHM 4905, DIS, Spring 99-

William Richard Mansfield, III, Student Assistant, Spring 97-Summer 97

Karyn M. Usher, Student Assistant, Spring 98-Summer 98

Charles Quincy Adams, Student Assistant, Fall 98

Stacie Kemp Wilensky, CHM 1051L, Spring 99

Andy Rodriguez, Student Assistant, Spring 99-Spring 2000

Marjoleine H. Bleijenberg, visiting undergraduate student form the Netherlands, Fall 2000-2002.

Cyrus Alexander Monroe, Honors’ in the Major student, CHM 4906, Fall 2000-Spring 2002. Graduated with the B.S. degrees in Chemistry and Biochemistry and successfully defended the honor’s thesis.  Thesis title:  “Inhibition Kinetics Study of Human Endometase, a Novel Matrix Metalloproteinase”. Honors’ Thesis was successfully defended in April, 2002.

Katherine (Katie) E. Berry, Swarthmore College, a Summer Undergraduate Award recipient, Department of Chemistry and Biochemistry, FSU, Summer 2002.

Joseph Lichter, CHM4905, DIS, and Honors’ Thesis (CHM4906) Spring 2002-Summer 2002.

Ehsan (Sonny) Achtchi, CHM4905, DIS, Fall 2002-Summer 2003.

Margie Coryn, Student Assistant. Fall 2002-Spring 2003.

Melanie Overland, CHM 1051L, Chemistry Freshman Honors student. Spring 2003

Colesha Jackson, a work study student funded by a minority scholarship from FSU, Spring 2003.

Shelbourn (Shelby) Kent, Honors’ in the Major student, CHM 4906, Summer 2002-Dec.2003.

Thesis title:  “Selective Inhibition of Matrix Metalloproteinase-26” successfully defended in Dec. 2003

Paul W. Dunk, CHM 4905, DIS, Spring 2004-Summer 2004.

Kevin Desai, Honors’ in the Major student, CHM 4906, Summer 2003-Summer 2005.

Honors Thesis title:  “An Immunohistochemical Study of Tissue Inhibitor of Metalloproteinase-4 and Matrix Metalloproteinase-26 in Human Prostate Tissue”. Honors’ Thesis was successfully defended in April, 2005.

Jennifer Walker, Howard Hughes Undergraduate Fellow, spring 2004-spring 2005.

Amjad Asker, CHM4905, DIS, Spring 2006.

Holly R. Monroe, CHM 4905, DIS, Fall 2005. Honors in the Major, Spring 2006-Spring 2007. Honors Thesis title:  “Identifying Molecular Markers of Early Invasive Human Breast Carcinoma”

Megan E. Muroski, CHM 1051L, CHM 4905, DIS, Fall 2003-Spring 2008

Kelli Wisniewski, CHM 4905, DIS, Spring 2008

Yangguang Ou, CHM 1051L, Spring 2008.  CHM 4905, DIS, Summer 2008

Clifford Matt Hill, CHM 4905, DIS, Spring 2010 –Spring 2011

Mark Katz, CHM 4905, DIS, Spring 2010, Summer 2010

Brittany Marlin, CHM 1051L, Honors Freshman Chemistry Laboratory, Spring 2010

Cathy St. Laurent, CHM 4905, DIS, Fall 2010.

Kelsie Decker-Pulice, CHM 1051L, Honors Freshman Chemistry Laboratory, Spring 2011; Women in Mathematics, Science, and Engineering (WIMSE) Research Experience Program, Fall 2011-

Luxi Qiao, CHM 4905, DIS, Fall 2011-Spring 2012

Skyler J. Ansel, BSC 4900r, Directed Individual Study (DIS), Fall 2011

Jessica A. Swinney, CHM 1051L, Honors Freshman Chemistry Laboratory, Spring 2012

Kaitlin M. Nicholson, CHM 4905, DIS, Summer 2012-Fall 2012.

Jennifer A. Luks, CHM 4905, DIS, Summer 2012-present

Cedric D. Sheffield, CHM 4905, DIS, Spring 2013-

Ty J. Lively, CHM 4905, DIS, Spring 2013-

                        Postdoctoral, Assistant Scholar/Scientists, and other Technical and Research Assistants/Associates (Sang as the Major Professor/Mentor):

Present:

Mark Druen Roycik, Ph.D., Fall 2010-present

Weixiong Xia, M.D., Dec. 2012-present

Betul BOZDOGAN PALA, Dec. 2012-present

Past:

Hui Li, M.S., Spring 95-Winter 97.

ShiDeng Bao, M.S., Spring 95.

XinYun Xu, M.S., Spring 97-Winter 97.

Wan-Qian Zhao, Ph.D. (D.DS), Summer 97-Fall 97.

Meng-Chun Jia, M.S., M.D. Winter 97-Summer 98.

Veera Lakshmi  Devi Badisa, M.S., Spring 98-Winter 98

Michaela Kroeger, Ph.D., Spring 98-Fall 98

J. Mike Magill, B.S., Fall 98-Spring 99

Sonia Hernandez-Barrantes, visiting graduate student, Spring 1999.

Ferry E. Gerkema, B.S., Research Assistant. Feb. 1999-Dec. 2000. 

Sara C. Monroe, B.S., Research Assistant, Summer 2000-present.

Laurence D. Covassin, Ph.D. Fall 2000-Spring 2001.

Asad Ullah, M..S. Fulbright Scholar/Visiting Student, Fall 2000-Summer 2001.

Hyun I. Park, Ph.D. Summer 1999-2003. 

Tiebang Kang, M.S.,  Ph.D. Summer 2001-2004.

Yunge Zhao, Ph.D., M.D.  Summer 99-2004.

Aizhen Xiao, M.S., M.D. Spring 2000-2004.

Ziad J. Sahab, Ph.D., Dec. 2005-April 2008.

Bin Qi, M.D., Oct. 2008-Oct. 2009

Back to the top

Abstracts and Posters Presented at Conferences

1. Q.-X. Sang, M. Dym, and S.W. Byers (1988) Sertoli cell plasma membrane associated and secreted plasminogen independent proteases (PIPs), J.Cell Biol. 107, 616a

2. Q.-X.Sang, M. Dym, and S.W. Byers (1988) Characterization of Sertoli cell plasma membrane associated and secreted plasminogen independent proteases, in Regulation of Testicular Function:  Signaling Molecules and Cell Cell Communications, 10th Annual Testis Workshop, 71a

3. S.W. Byers, Q.-X. Sang, H.N. Dai, J. Beaudry, and B. Hoxter (1989) The Sertoli cell plasma membrane and plasminogen independent proteases in seminiferous epithelium remodeling, in Serono Symposia Review, Supplement I, IV International Congress of Andrology, 21a

4. S.W. Byers, Q.-X. Sang, H.N. Dai, J. Beaudry, and B. Hoxter (1989) Isolation and characterization of Sertoli cell plasma membrane and junctional specializations, Anatomical Record 223, 20a

5. Q.-X. Sang, and S.W. Byers (1989) Matrix metalloproteinases in rat testicular cell culture, J.Cell Biol. 109, 135a

6. Q.-X. Sang, D. Grant, E.W. Thompson, W.G. Stetler Stevenson, and S.W. Byers (1990) Soluble laminin and RGD containing peptides differentially regulate type IV collagenase mRNA, activation and localization in testicular cell culture, J.Cell Biol. 111, 15a

7. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart, (1993) Activation of human neutrophil progelatinase/type IV collagenase by matrilysin and fibroblast collagenase, Molecular Biology of the Cell (suppl.), 4, 287a

8. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1994) Activation of human progelatinase A and B (type IV collagenases) by matrilysin and fibroblast collagenase,  Molecular Genetics of Tumor Progression and Metastasis -- A Special Conference of the American Association for Cancer Research, page B-26

9. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Regulation of human type IV collagenase activity.  The American Cancer Society, Florida Division, Inc., 18th Annual Seminar of Florida Cancer Researchers. 3/25/1995, Orlando, Florida.

10. Q.-X. Sang and J.M. Caffrey (1995)  Hydrolysis of porcine ceruloplasmin by human leukocyte elastase.  Cambridge Healthtech Institute's Angiogenesis Antagonists -- New Cancer Strategies.  Washington D.C.  Poster #5.

11. Q.-X. Sang, H. Birkedal-Hansen, and H.E. Van Wart (1995) Proteolytic activation of progelatinases A and B. Gordon Research Conference on Matrix Metalloproteinase, Proctor Academy, Andover, NH.  July 16-21, 1995.

12. Q.A. Sang and H. Li (1996) Regulation of breast cancer type IV collagenase activity by laminin and laminin-derived peptides.  Proteases and Protease Inhibitors in Cancer.  A Special Conference of American Association for Cancer Research, page A-31.  Panama City Beach, Florida, March 1-5, 1996.

13. D.A. Douglas and Q.A. Sang (1996) Computational sequence analysis of the matrix metalloproteinase family.  The American Cancer Society, Florida Division, Inc., 19th Annual Seminar of Florida Cancer Researchers. 3/30/1996, Orlando, Florida. Talk # 7.

14. D.D. Bauzon, M.A. Stolow, Y.-B. Shi, and Q.A. Sang (1996)  Identification and characterization of a novel collagenase in Xenopus laevis.  The American Cancer Society, Florida Division, Inc., 19th Annual Seminar of Florida Cancer Researchers. 3/30/1996, Orlando, Florida.  Talk # 20.

15. Hui Li and Q.A. Sang (1996)   Regulation of breast cancer type IV collagenase activity by laminin and laminin-derived peptides.  The American Cancer Society, Florida Division, Inc., 19th Annual Seminar of Florida Cancer Researchers. 3/30/1996, Orlando, Florida.  Poster # 44.

16. Q.A. Sang, H. Li, and D.D. Bauzon (1996) Activation of breast cancer type IV collagenases.  Gordon Research Conference on Basement Membrane.  New England College, Henniker, NH.  June 9-14, 1996.

17. Q.A. Sang and D.A. Douglas (1996) Computational sequence analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases,   Gordon Research Conference on Proteolytic Enzymes and Their Inhibitors.  Colby-Sawyer, New Hampshire.  July 21-26, 1996.

18. D.D. Bauzon, J. Li, M.A. Stolow, Y.-B. Shi, and Q.A. Sang (1996) Biochemical characterization of a novel collagenase from Xenopus laevis.  Mol. Biol. Cell (suppl.) 7, 59a.

19. H. Li, D.D. Bauzon, and Q.A. Sang (1997) Cell surface metalloproteinase in breast cancer cells and fibroblasts. Fibronectins, Integrins and Related Molecules, Gordon Research Conference.  Ventura, CA,  January 26-31, 1997.

20. H. Li, D.D. Bauzon, and Q.A. Sang (1997)   Breast cancer membrane type-1 matrix metalloproteinases.  Poster #34, American Chemical Society, Florida Sections, 1997 Annual Meeting, May 2 & 3, 1997.  Orlando, Florida.

21. B. C. Patterson and Q.A. Sang (1997)  Potential angiostatin converting enzyme activities of human matrilysin and gelatinase B.  Poster #35,  American Chemical Society, Florida Sections, 1997 Annual Meeting, May 2 & 3, 1997.  Orlando, Florida.

22. D. E. Bauzon, J.M. Magill, L.J. Windsor, J.W. Li, Y.-B. Shi, and Q.A. Sang (1997)   Hydrolysis of type I, II, and III collagens by frog collagenase-4.  Poster #36, American Chemical Society, Florida Sections, 1997 Annual Meeting, May 2 & 3, 1997.  Orlando, Florida.

23. Q.X.A. Sang, Y.E. Shi, and D.A. Douglas (1997) Computational sequence analysis of matrix metalloproteinases and their tissue inhibitors.  Cambridge Healthtech Institute.   Beyond the Human Genome Project, from Genes to Proteins and Bioinformatics.   June 9-12, 1997.  San Francisco, California.

24. D.D. Bauzon, L.J. Windsor, J. Li, Y.-B. Shi, and Q.A. Sang, Substrate specificities of frog collagenase-4 (MMP-18).  Gordon Research Conference on Matrix Metalloproteinase, Proctor Academy, Andover, NH.  July 13-18, 1997.

25. H.Li, D.D. Bauzon, and Q.A. Sang, Novel human breast cancer cell surface metalloproteinases.  Gordon Research Conference on Cancer, Salve Regina, RI. August 3-8, 1997.

26. B.C. Patterson and Q.A. Sang, Human matrilysin and gelatinase B, candidates for angiostatin converting enzymes.   Gordon Research Conference on Angiogenesis and Microcirculation, Salve Regina, RI. August 17-22, 1997.

27. S.C. Mueller, G. Ghersi, S.K. Akiyama, Q.X.A. Sang, L. Howard, M. Pineiro-Sanchez, H. Nakahara, Y. Yeh, and W.-T. Chen (1997) Collagen induces ?1 integrin docking of a membrane-bound gelatinase, seprase, at plasma membrane sites of tumor cell invasion.  Mol. Biol. Cell (suppl.), 8, 75a

28. Q.X.A. Sang, Y.E. Shi, and H. Li (1998)  Biochemical characterization of human tissue inhibitor of metalloproteinase-4.  Keystone Symposium on Angiogenesis and Vascular Remodeling.  Steamboat Springs, Colorado.  March 28-April 3, 1998.

29. Q.X.A. Sang, H. Li, X. Xu, Y.E. Shi, M.-C. Jia.  Tissue inhibitor of metalloproteinase-4 in human breast cancer and endothelial cells.  Proeases and Protease Inhibitors in Cancer.  A Special Conference of American Association for Cancer Research and ACTA Pathologica Microbiologica Immunologica Scandinavia.  Nyborg, Denmark.  June 14-18, 1998.

30. Q.X.A. Sang. Complex role of matrilysin and type IV collagenases in angiogenesis.  Oral Presentation.  In Vascular Endothelium: Mechanisms of Cell Signaling.  Edited by J.D. Catravas, A.D. Callow, U.S. Ryan.  NATO Science Series.  Series A: Life Sciences. Vol. 308, p. 231. IOS Press. 1999. Amsterdam.  NATO Advanced Study Institute.  Crete, Greece.  June 20-29, 1998.

31. Q.X.A. Sang, X. Xu, Y.E. Shi, H. Li.  Tissue inhibitor of metalloproteinase-4 in human breast cancer and endothelial cells. In Vascular Endothelium: Mechanisms of Cell Signaling.  Edited by J.D. Catravas, A.D. Callow, U.S. Ryan.  NATO Science Series.  Series A: Life Sciences. Vol. 308, p. 270.  IOS Press. 1999. Amsterdam.  NATO Advanced Study Institute.  Crete, Greece.  June 20-29, 1998.

32. Q.X.A. Sang, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau.  Targeting matrix metalloproteinases in human prostate cancer. Inhibition of Matrix Metalloproteinases:  Therapeutic Applications.  A New York Academy of Sciences Conference.  Tampa, Florida.  October 21-24, 1998.

33. Q.X.A. Sang, M.A. Schwartz, H. Li, L.W.K. Chung, and H.E. Zhau.  Inhibition of prostate cancer matrix metalloproteinases.  Metalloproteases: Chemistry, Biology and Medicine.  A Keystone Symposium on Molecular & Cellular Biology, Tamarron, Colorado, Feb. 25-March 3, 1999.  Organizers:   H. Nagase, J.F. Woessner, Jr., J.S. Bond.

34. M.-C. Jia, M.A. Schwartz, V.L.D. Badisa, M.A. Ghaffari, Y.-L. Luo, M.C. Jaye, H.K. Kleinman, Q.X.A. Sang.  Matrixins and metalloproteinase inhibitors in human endothelial cell growth, differentiation, and angiogenesis. 5th Biannual International Conference on Angiogenesis: From the Molecular to Integrative Pharmacology.  Crete, Greece.  July 1-7, 1999.

35. M.-C. Jia, M.A. Schwartz, V.L.D. Badisa, M.A. Ghaffari, Y.-L. Luo, M.C. Jaye, H.K. Kleinman, Q.X.A. Sang.  Inhibition of human endothelial cell growth, differentiation, and angiogenesis by novel synthetic metalloproteinase inhibitors.  Gordon Research Conference on Matrix Metalloproteinases.  Colby-Sawyer College, New London, New Hampshire.  August 8-13, 1999.

36. Q.X.A. Sang, M.A. Schwartz, and M.-C. Jia.  Targeting angiogenesis and cancer invasion with metalloproteinase inhibitors.  2nd International Conference on Protease Inhibitors.  Gainesville, Florida.  December 3-6, 1999.

37. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.  Expression, activation, and inhibition of a novel matrix metalloproteinase, endometase.    An International Symposium “Proteinase Inhibitors and Activators” Strategic Targets for Therapeutic Intervention.  University of Oxford, England, UK.  April 17-20, 2000.

38. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.  Endometase, a NovelMatrixin Derived from Human Endometrial Tumor and Endothelium.  NATO Conference on  Vascular Endothelium: Source and Target of Inflammatory Mediators.  NATO Advanced Study Institute.  Crete, Greece.  June 24-July 3, 2000.

39. Hurst DR, Li H, Badisa VLD, Shi YE, Sang QX.  Characterization of a polyclonal antibody specifically against tissue inhibitor of metalloproteinases 4 in human breast cancer. ECM 2000:  International Conference on the Biology and Pathology of the Extracellular Matrix.  St. Louis, Missouri.  October 12-15, 2000.

40. H.I. Park, J. Ni, F.E. Gerkema, L. Ding, V.E. Belozerov, and Q.-X. Sang.  Biochemical characterization of human endometase (MMP-26) from endometrial tumor.  ECM 2000: International Conference on the Biology and Pathology of the Extracellular Matrix.  St. Louis, Missouri.  October 12-15, 2000.

41. H.I. Park, M.A. Schwartz, and Q.-X. Sang.  Structure-function relationship of human endometase active site.  4th Biannual Structural Biology Symposium. Computational Structural Biology:  From Simulation to Experiment & Back.  Florida State University, Tallahassee, Florida.  January 18-21, 2001.

42. Q.-X.A. Sang, H.I. Park, J. Ni, D. Liu, F.E. Gerkema, and Y.-G. Zhao. Discovery of a novel matrix metalloproteinase (MMP-26), endometase, from human endometrial and prostate cancers. 5th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association,“Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21st Century”.  Poster B1.  Maui, Hawaii.  February 12-16, 2001.

43. Q.-X. A. Sang, J. Ni, F.E. Gerkema, D. Liu, V.E. Belozerov, and H. I. Park (2001) Biochemical properties of human endometase/MMP-26, a unique new metalloproteinase specifically expressed in uterus, placenta, and cancer cells. American Society for Biochemistry and Molecular Biology Annual Meeting held jointly with Experimental Biology.  Orlando, Florida.  March 30-April 6, 2001. FASEB J.  15 (4), page A189

44. Y.-G. Zhao, P. Wei, L. Zhuang, S. Ruben S, Q.-X. Sang (2001)  Human disintegrin and metalloproteinase ADAM19 (hADAM19):  Cloning, expression and enzymatic characterization.  American Society for Biochemistry and Molecular Biology Annual Meeting held jointly with Experimental Biology.  Orlando, Florida.  March 30-April 6, 2001. FASEB J.  15 (4), page A189

45. D.R. Hurst, M.A. Schwartz, M.A. Ghaffari, H. Tschesche, Q.-X. Sang (2001).  New thiol metalloproteinase inhibitors:  an examination of the catalytic domain of membrane-type 1 matrix metalloproteinase in human breast cancer.  American Society for Biochemistry and Molecular Biology Annual Meeting held jointly with Experimental Biology.  Orlando, Florida.  March 30-April 6, 2001. FASEB J.  15 (4),  page A539.

46. Y.-G. Zhao,  P. Wei, L. Zhuang, D.R. Hurst, S. Ruben  and Q.-X. Sang.  Immunological and enzymatic characterization of human disintegrin and metalloproteinase 19 (hADAM 19)/Meltrin beta. Cold Spring Harbor Laboratory Meeting on Proteolysis and Biological Control. Cold Spring Harbor, NY. May 2-6, 2001.

47. H.I. Park, J. Ni, F.E. Gerkema, F.-L. Yu, Y.-G. Zhao, V.E. Belozerov, D. Liu, M.A. Schwartz, L. J. Windsor, and Q.-X. A. Sang.  Discovery and characterization of human endometase/MMP-26, a unique new metalloproteinase specifically expressed in uterus, placenta, and cancer Cells.  Gordon Research Conference on Matrix Metalloproteinase.  Italy, May 13-18, 2001.

48. Y.-G. Zhao, P. Wei, L. Zhuang, L.D. Covassin, D.R. Hurst, S. Ruben, and Q.-X. Sang.  Human disintegrin and metalloproteinase 19, expression, characterization, and potential functions.  International Congress on Membrane-bound Proteolytic Enzymes and Cancer”.  Palermo, Italy.  May 19-21, 2001.

49. H.I. Park, J. Ni, F.E. Gerkema, F. Yu, Y.-G. Zhao, D. Liu, M.A. Schwartz, L.J. Windsor, and Q.-X. Sang.  Discovery of a novel angiogenesis and cancer-associated human matrix metalloproteinase MMP-26/endometase.  6th Biannual International Conference on Angiogenesis: Basic Science and Clinical Developments.  Crete, Greece.  June 26-July 1, 2001.

50. Y.-G. Zhao, P. Wei, L. Zhuang, L.D. Covassin, D.R. Hurst, S. Ruben, and Q.-X. Sang. Identification of human adamalysin-19 (disintegrin and metalloproteinase 19) and its putative functions in cardiovascular system and cancer. 6th Biannual International Conference on Angiogenesis: Basic Science and Clinical Developments.  Crete, Greece.  June 26-July 1, 2001.

51. H.I. Park, M.A. Schwartz, and Q.-X. Sang.  Structure-function relationship of the active site in human endometase (MMP-26) from endometrial tumor.  American Association for Cancer Research Workshop “Pathology of Cancer”, the Edward A. Smuckler Memorial Workshop.  Keystone, Colorado.  July 15-22, 2001.

52. H.I. Park, Y.-G. Zhao, T.-B. Kang, E. Filenova, M.A. Schwartz,  J. Ni, F. Yu,  L.J. Windsor, and Q.-X. Sang.  Human matrix metalloproteinase-26 in cancer:  substrate specificity, inhibition profile, and potential functions. “Imaging in 2020 Conference” organized by the California Institute of Technology and National Cancer Institute.  Jackson Hole, Wyoming.  September 29, 2001-October 4, 2001.

53. D.R. Hurst, M.A. Schwartz, Y.-H. Jin, M.A. Ghaffari, H. Tschesche, and Q.-X. Sang.  New mercaptoalkylsulfide inhibitors targeting membrane-type 1 matrix metalloproteinase.  2nd General Meeting of the International Proteolysis Society associated with the International Conference on Protease Inhibitors.  Freising, Germany. October 31-November 4, 2001.

54. H.I. Park, J. Ni, F.-L. Yu, Y.-G. Zhao, E. Filenova, M.A. Schwartz, L.J. Windsor, and Q.X. Sang.  Human endometase/MMP-26 may be a novel marker for carcinoma diagnosis and a new target for cancer treatment. 2nd General Meeting of the International Proteolysis Society associated with the International Conference on Protease Inhibitors.  Freising, Germany. October 31-November 4, 2001.

55. Y.-G. Zhao, P. Wei, L. Zhuang, D.R. Hurst, L.D. Covassin, S. Ruben, and Q.-X. Sang.  Human membrane adamalysin-19 expression, enzymatic activity, and neutralizing antibodies. 2nd General Meeting of the International Proteolysis Society associated with the International Conference on Protease Inhibitors.  Freising, Germany. October 31-November 4, 2001.

56. H.I. Park, Y.-G. Zhao, T.-B. Kang, E. Filenova, F.-L. Yu, M.A. Schwartz, and Q.-X.A. Sang.  Endometase/Matrilysin-2 in Human Endometrial, Breast, and Prostate Cancers. Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications In Vivo. An American Association for Cancer Research (AACR) Special Conference in Cancer Research. Lake Buena Vista, FL. January 23-27, 2002.

57. C.A. Monroe, Y.-H. Jin, M. Ghaffari, H.I. Park, M.A. Schwartz, and Q.-X. Sang.  The biochemical characterization of human endometase. 2001-2002 Summer Undergraduate Research Program, Pfizer Global Research & Development. Groton Laboratories, Groton Connecticut, USA.  April 5, 2002.

58. T. Kang, Y.-G. Zhao, D. Pei, J.F. Sucic, and Q.-X. Sang. Molecular Mechanism of Intracellular Activation of Human Adamalysin 19 (hADAM19 or Meltrin Beta) by a Proprotein Convertase Furin.  Gordon Research Conference on Proteolytic Enzymes and Their Inhibitors.  Colby-Sawyer College, New London, New Hampshire.  July 7-12, 2002

59. Y.-G. Zhao, H.I. Park, M.A. Schwartz, M.-C. Jia, and Q.-X. Sang.  A New Metalloproteinase in Cancer Progression and Angiogenesis.  Pathobiology of Cancer Workshop.  American Association for Cancer Research. Keystone, Colorado.  July 14-21, 2002.

60. D.R. Hurst, M.A. Schwartz, Y.-H. Jin, M.A. Ghaffari, H. Tschesche, and Q.-X. A. Sang.  Targeting membrane type 1-matrix metalloproteinase with mercaptoalkylsulfide inhibitors.  Era of Hope, Department of Defense Breast Cancer Research Program Meeting.  Proceedings vol. II, p27-4. Orlando, Florida. September 25-28, 2002.

61. Y.-G. Zhao, A.-Z. Xiao, T. Kang, L.W.K. Chung, M.G. Swanson, H.E. Zhau, J. Kurhanewicz, and Q.-X.A. Sang.  Putative Role of Endometase/Matrilysin-2 in Prostate Cancer Cell Invasion. An American Association for Cancer Research Special Conference on Proteases, Extracellular Matrix, and Cancer. Hilton Head Island, South Carolina. October 9-13, 2002.

62. H.I. Park, Y.-H. Jin, C.A. Monroe, S.C. Monroe, M.A. Schwartz, and Q.-X. A. Sang. Inhibition Characteristics of a New Matrix Metalloproteinase MMP-26: Selectivity in Nonprime Site.  An American Association for Cancer Research Special Conference on Proteases, Extracellular Matrix, and Cancer. Hilton Head Island, South Carolina. October 9-13, 2002.

63. D.R. Hurst, M.A. Schwartz, Y. Jin, H. Tschesche, and Q.-X.A. Sang. Exploring the Active Site of Membrane Type 1-Matrix Metalloproteinase with New Mercaptosulfide Inhibitors. 54th Southeast Regional Meeting of the American Chemical Society. Charleston, SC, November 14, 2002.

64. T. Kang, H. Tschesche, and Q.-X. A. Sang. Regulation of Enzyme Stability by the Cysteine Residues of the Residual Cysteine-rich Domain of the C-terminal Fragment Retained by the Autocatalytic Processing at Glu586-Ser587 of Human Adamalysin 19/ADAM19. Gordon Research Conference on Matrix Metalloproteinase.  Conference Chairpersons:  Christopher M. Overall and Zena Werb.  Big Sky, Montana.  August 17-22, 2003.

65. Y.-G. Zhao, A.-Z. Xiao, H.I. Park, R.G. Newcomer, M. Yan, Y.-G. Man, S.C. Heffelfinger, and Q.-X. Sang (2003) Endometase in human breast carcinomas, selective activation of progelatinase B and inhibition by tissue inhibitors of metalloproteinases-2 and -4. 26th Annual San Antonio Breast Cancer Symposium. Dec. 3-6, 2003. Poster no. 271. Special Issue. Breast Cancer Res. Treat. 82, Suppl. 1, S64.

66. Y.-G. Man, R. Mattu, R. Zhang, M. Yousefi, Q.X.A. Sang, and T. Shen (2003) A subset of normal and hyperplastic appearing mammary ductal cells display invasive features. 26th Annual San Antonio Breast Cancer Symposium. Dec. 3-6, 2003. Poster no. 573. Special Issue. Breast Cancer Res. Treat. 82, Suppl. 1, S141.

67. Y.-G. Man, R. Zhang, R. Mattu, T. Shen, and Q.X.A. Sang (2003) A subset of mammary epithelial cells overlying focally disrupted myoepithelial cell layers shows an unusual immunostaining pattern for proliferation-related proteins. 26th Annual San Antonio Breast Cancer Symposium. Dec. 3-6, 2003. Poster no. 670. Special Issue. Breast Cancer Res. Treat. 82, Suppl. 1, S163.

68. Q.-X. Sang, H.I. Park, Y. Jin, Y. Zhao, A. Xiao, D.R. Hurst, C.A. Monroe, S. Lee, R.G. Newcomer, M.A. Schwartz (2004) Inhibition of endometase/matrilysin-2 by tissue inhibitors of metalloproteinases and new synthetic mercaptosulfide inhibitiors and implications in human prostate and breast cancers.  Proc. Am. Assoc. Cancer Res. 45, Abst. No. 1835, March 29, 2004.

69. Y.-G. Man, T. Shen, Y. Zhao, and Q.-X. Sang (2004) Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: implications for tumor invasion. Proc. Am. Assoc. Cancer Res. 45, Abst. No. 1775, March 29, 2004.

70. Y.-G. Man, T. Shen, Y. Zhao, and Q.-X. Sang (2004) Morphologically comparable prostate acini and ducts with and without a focal basal cell layer disruption have a different cell proliferation rate: implications for tumor invasion. FASEB J. 18 (5), p. A1183. Abst. No. 786.11. April 21, 2004.

71. Man YG, Shen T, Zhao YG, Sang QX (2004). Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events:  Implications for basal call layer degradation and tumor invasion. Int. Symposium on Predictive Oncol. And intervention Strategies, Nice, France, Feb. 7-10, 2004. Cancer Detection & Prevention, 2004 Symposium Issue S-51: 15.

72. Hurst DR, Schwartz MA, Jin Y, Ghaffari MA, and Sang QXA (2004) Inhibition Characteristics of Membrane Type 1-Matrix Metalloproteinase with Novel Mercaptosulfide Inhibitors. “Pathobiology of Cancer Workshop” organized by NCI and AACR. Snowmass Village, CO, July 18-25, 2004.

73. Y.-G. Man, T. Shen, Y.-G. Zhao, and Q.-X. A. Sang (2004) Prostate basal cell layer disruptions and leukocyte infiltration (Endometase/matrilysin-2 in invasion and inflammation). 10th Prouts Neck Meeting on Prostate Cancer. Late Stage Prostate Cancer: a Multidisciplinary Approach. pp. 60. Nov. 4-7, 2004. Black Point Inn, Prouts Neck, Maine. Organized by the National Cancer Institute and University of Pittsburgh Cancer Institute.

74. S. Lee and Q.-X. Sang (2004) The role of calcium ions in the structure and function of matrixmetalloproteinase-26. 56th Southeast Regional Meeting of the American Chemical Society. Research Triangle Park, NC, November 11, 2004.

75. Y.-G. Man and Q.-X. A. Sang (2004) Human prostate basal cell layer disruptions and leukocyte infiltration. American Association for Cancer Research Special Conference on Basic, Translational, and Clinical Advances in Prostate Cancer. Poster A5. Nov. 17-21, 2004. Bonita Springs, Florida.

76. Y. Zhao, A. Xiao, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2004) Inhibition of MDA-MB-435 cell invasion by a synthetic matrix metalloproteinase inhibitor. The American Society for Cell Biology 44th Annual Meeting, December 4-8, 2004 Washington DC. Page 179, abstract # 2344, Poster # B351.

77. Q.-X. Sang, Y.-G. Zhao, and Y.-G. Man (2005) Mechanism of human prostate cancer invasion: Basement membrane degradation and basal cell layer disruption. Proceedings of American Association for Cancer Research 46, page 1106, Poster #4689. April 16-20, 2005. Anaheim, California.

78. Y.-G. Man, P.E. Berg, Q.-X. Sang (2005) Differential expression of tumor invasion related proteins in cells overlying focally disrupted myoepithelial cell layers and adjacent cells within the same duct. Era of Hope: Proceedings of Department of Defense Breast Cancer Research Program Meeting Poster P10-5, p75. June 8-11, 2005. Philadelphia, Pennsylvania.

79. Y. Zhao, A. Xiao, and Q.-X. Sang (2005) The novel three dimensional cell culture system for human breast cancer: cancer invasion and cell-cell interaction. Era of Hope: Proceedings of Department of Defense Breast Cancer Research Program Meeting Poster P59-24, p417. June 8-11, 2005. Philadelphia, Pennsylvania.

80. M.E. Muroski, D. R. Hurst, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2005) Potency and Selectivity of Selected Metalloproteinase Inhibitors. 37th Annual Southeast Regional American Chemical Society Undergraduate Research Conference hosted by Mississippi State University, March 31-April 1st, 2005. Poster no. 1. Poster book p. 22.

81. M.E. Muroski, D.R. Hurst, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2005) Potency and Selectivity of Selected Metalloproteinase Inhibitors. 37th Annual Southeast Regional American Chemical Society Undergraduate Research Conference hosted by Mississippi State University, March 31-April 1st, 2005. Oral Presentation no 1. Poster book, p. 4.

82. K.K. Desai, R.G. Newcomer, K.A. Iczkowski, Y.-G. Zhao, M.D. Roycik, and Q.X.A. Sang (2005) Expression levels of tissue inhibitor of metalloproteinases-4 and matrix metalloproteinase-26 correlate with the invasive potential of HGPIN in human prostate tissue. 37th Annual Southeast Regional American Chemical Society Undergraduate Research Conference, Mississippi State University, March 31-April 1, 2005.

83. Y.G. Man and Q.-X. Sang (2005) Myoepithelial cell layer disruption and human breast cancer invasion. Breast Cancer Research. Vol. 7, Suppl. 2, June 2005. Poster P3.06, p. S33. The Third International Symposium on the Molecular Biology of Breast Cancer. Molde, Norway, 22-26 June 2005.

84. Sahab, Z.J., and Sang, Q.-X. (2005) Albumin elimination from human plasma. Abstracts of Papers, 230th American Chemical Society National Meeting, Washington, DC, U.S., Aug. 28-Sept. 1, 2005, ANYL-150.  CODEN: 69HFCL AN 2005:736142.

85. Sahab, Z.J., Suh, Y., and Sang, Q.-X. (2005) Pre-fractionation of proteins from crude biological samples prior to 2-D gel electrophoresis. Abstracts of Papers, 230th American Chemical Society National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 , ANYL-151.  CODEN: 69HFCL AN 2005:736143.

86. Sahab, Z.J., Suh, Y., and Sang, Q.-X. (2005) Narrow isoelectric-point based pre-fractionation of proteins from crude biological samples.  Abstracts of Papers, 230th American Chemical Society National Meeting, Washington, DC, U.S., Aug. 28-Sept. 1, 2005, ANYL-246.  CODEN: 69HFCL AN 2005:736238.

87. D.R. Hurst, M.A. Schwartz,Y. Jin, M.A. Ghaffari, P. Kozarekar, J. Cao, Q.-X. Sang (2005) Inhibition of enzyme activity and cell-mediated substrate cleavage of membrane type 1-matrix metalloproteinase by newly developed mercaptosulfide inhibitors. Matrix Metalloproteinases Gordon Research Conference, Big Sky, Montana. Aug. 28-Sept. 2, 2005. Poster number 118.

88. Y. Jin, Q. Cao, Q.-X. Sang and M.A. Schwartz (2006) Zinc Metalloproteinase Inhibitors with 1,2-Dihydroxy benzene and 3-Hydroxy-4-pyrone as Zinc Binding Groups. 231st American Chemical Society National Meeting & Exposition, March 26-30, 2006, Atlanta, Georgia.

89. S. Lee and Q.-X. Sang (2006) Effects of human endometase/matrilysin-2/MMP-26 on the invasive potential and protein expression patterns of a human breast cancer cell line MDA-MB-231. American Chemical Society (ACS) Paper #36620 - 58th Southeast Regional Meeting. November 1-4, 2006. Augusta, Georgia.

90. Q.-X. Sang, S. Lee, H.I. Park, Y.-G. Zhao, Y. Jin, and M.A. Schwartz (2007) Unique Structure and Function of Endometase/Matrilysin-2, a Putative Cancer Biomarker. Invited Plenary Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007. Talk number 115.

91. R.G. Newcomer, M.D. Moussallem, T.C. S. Keller, J.B. Schlenoff, and Q.-X. Sang (2007)  Divergent Human Vascular Smooth Muscle Cell Response to Polyelectrolyte Multilayer Bio-Interfaces. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007.  Talk number 114.

92. S.M. Semaan, Z.J. Sahab, Y. Suh, and Q.-X. Sang (2007) Extraction of Basic Proteins using Batch Anion Exchange Chromatography Prior to Profiling and Identification. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 10-12, 2007.  Poster number 224.

93. Y. Jin, Q. Cao, C. Ben, Q.-X. Sang, and M.A. Schwartz (2007) Design and Syntheses of Novel MMP Inhibitors Containing a Mercaptosulphonamide Zinc-bind Group. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 10, 2007.  Talk number 46.

94. Q.-X. Sang, S. Lee, H.I. Park, Y.G. Zhao, Y. Jin, K.K. Desai, and M.A. Schwartz (2007) Endometase/Matrilysin-2/MMP-26 is a Putative Biomarker for Early Stage of Cancer of Human Breast and Prostate.  Gordon Research Conference on Matrix Metalloproteinases. II Ciocco, in Lucca (Barga), Italy. June 3-8, 2007.

95. Q.-X. Sang, Y. Jin, Y.-G. Zhao, H.I. Park, A.-Z. Xiao, R.G. Newcomer, T. Kang, S. Lee, L.W.K. Chung, H.E. Zhau, and M.A. Schwartz (2007) Endometase/Matrilysin-2/Matrix Metalloproteinase-26 as a Putative Biomarker for Early Stage of Human Prostate Cancer. Innovative Minds in Prostate Cancer Today (IMPaCT) Meeting, Congressionally Directed Medical Research Programs, Prostate Cancer Research Program. Atlanta, Georgia. September 5-8, 2007.

96. Y. Yang, J.F. Thompson, E.J. Walker, E. Candelario-Jalil, E.Y. Estrada, L. Li, R.R. Reichard, R. Khokha, C. Ben, Q.-X. A. Sang, L.A. Cunningham, G.A. Rosenberg (2007) Tissue inhibitor of metalloproteinase-3 (TIMP-3) facilitates delayed oligodendrocyte death in focal cerebral ischemia in rodent. Neuroscience 2007. San Diego, California. November 3-7, 2007.

97. Q.-X. Sang, Z.J. Sahab, Y.-G. Man, R.G. Newcomer (2008) Differential protein expression between microdissected estrogen-receptor positive and negative human breast cancer tissues. Invited Talk. American Chemical Society, Florida Section FAME Meeting, Orlando, Florida. May 9, 2008. Talk number 58.

98. Z. I. Khamis, Z.J. Sahab, and Q.-X. Sang (2008) Proteomics of human prostate tumor microenvironment to identify proteins involved in the progression from benign to invasive cancer.  American Chemical Society, Florida Section FAME Meeting, Orlando, Florida. May 8-10, 2008. Poster Presentation.

99. Q.-X. Sang (2008) Protein Biomarkers of Human Breast and Prostate Cancer Invasion and Progression at the Interface of Benign and Malignant Tumors. BIT’s Annual World Cancer Congress 2008. Invited talk at the session 32 on Cancer Invasion and Metastasis. Shanghai, China. June 13, 2008.

100. M.D. Roycik, Q. Cao, C.S. Yun, Y. Jin, S.M. Hira, M.A. Schwartz, G.F. Strouse, and Q.-X. Sang (2008) Role of Human Mesenchymal Stem Cells and Matrix Metalloproteinases in Vascular Wound Healing. Poster number 26, Page 30. First Southeast Stem Cell Consortium, University of Georgia, Athens, GA. October 23-24, 2008.

101. Q.-X. Sang (2009) Metzincin clan of metalloproteinases as therapeutic targets. American Chemical Society 237th National Meeting & Exposition. Invited talk, the Recent Developments in Metalloprotease Inhibitors Session, Division of Medicinal Chemistry. March 23, 2009. Paper ID: 1246333 and paper number: 140. Salt Lake City, UT. March 22-March 27, 2009.

102. Q.-X. Sang, Y. Jin, S. Lee, Q. Cao, C. Ben, M.D. Roycik, B. Qi, and M.A. Schwartz (2009) Metzincin metalloproteases and their functions in cancer, stroke, and inflammatory diseases. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 15, 2009. Invited Talk. Abstract number 54.

103. C. Ben, W.-Y. Yang, I. Alabugin, Q.-X. Sang (2009) Application of photoactivatable compounds to target human prostate cancer and induce apoptosis. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 14, 2009. Poster number 12; Abstract number 168.

104. B. Qi, Q.-X. Sang (2009) Two-dimensional gel electrophoresis screens metastasis related proteins in nasopharyngeal carcinoma cell lines. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 14, 2009. Poster number 23; Abstract number 179.

105. Q. Cao, Y. Jin, M.A. Schwartz, C. Ben, M.D. Roycik, and Q.-X. Sang (2009) Targeting metalloproteinases involved in stroke-associated blood brain barrier permeability. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 14, 2009. Poster number 40; Abstract number 196.

106. M.D. Roycik, Q. Cao, Y. Jin, S.M. Hira, C. Breshike, G.F. Strouse, M.A. Schwartz, and Q.-X. Sang (2009) Investigation of matrix metalloproteinases in human mesenchymal stem cells towards mechanisms for cardiac repair. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 15, 2009. Poster number 40; Abstract number 240.

107. Q.-X. Sang, Q. Cao, M.D. Roycik, Y. Jin, C.Ben, and Martin A. Schwartz (2009) Human Metalloproteinases and Their Inhibitors in Microvascular Wound Healing, Blood-Brain Barrier Permeability, and Adult Mesenchymal Stem Cell Differentiation. Atherosclerosis Gordon Research Conference. Tilton School in Tilton, NH. June 21-26, 2009.

108. Q.-X. Sang, Q. Cao, M.D. Roycik, Y. Jin, C. Ben, and Martin A. Schwartz (2009) Role of Human Matrix Metalloproteinases and Mesenchymal Stem Cells in Microvascular Endothelial Wound Healing and 3-D Blood-Brain Barrier Permeability. Gordon Research Conference on Biomaterials: Biocompatibility/Tissue Engineering. Holderness School in Holderness, NH. July 19-24, 2009.

109. Q.-X. Sang, M.D. Roycik, Q. Cao, Y. Jin, C. Ben, and M.A. Schwartz (2009) Role of Human Matrix Metalloproteinases and Their Inhibitors in Mesenchymal Stem Cell Differentiation and Vascular Endothelial and Smooth Muscle Cell Wound Healing. NIH, NHLBI Symposium on Cardiovascular Regenerative Medicine. Poster Presentation. Bethesda, Maryland, October 14-15, 2009.

110. M.D. Roycik, Q. Cao, Y. Jin, D.B. Bosco, M.A. Schwartz, and Q.-X. Sang (2009) Exploring Roles of Matrix Metalloproteinases in Human Mesenchymal Stem Cell Differentiation with Novel Synthetic Inhibitors. Invited Talk. Page 22, 2nd Southeast Stem Cell Consortium Workshop Program. Paul D. Coverdell Center, University of Georgia, Athens, GA. October 15-16, 2009.

111. Q. Cao, M.D. Roycik, Y. Jin, D.B. Bosco, M.A. Schwartz, and Q.-X. Sang (2009) Investigation on co-culture model of human mesenchymal stem cell and human brain microvascular endothelial cell treated with novel synthetic matrix metalloproteinase inhibitors. Poster presentation number 22. Page 23, 2nd Southeast Stem Cell Consortium Workshop Program. Paul D. Coverdell Center, University of Georgia, Athens, GA. October 15-16, 2009.

112. Q.-X. Sang. Challenges of identifying biomarkers of human cancer invasion and metastasis. Georgia State Biotechnology Symposium, 2009. Advances in Cancer Research:  Biomarker Detection – Epigenetic Gene Regulation. Invited Talk. November 23-24, 2009. Atlanta, Georgia.

113. Z.I. Khamis, K.A. Iczkowski, and Q.-X. Sang (2010) Protein biomarkers of human prostate cancer stromal cells. American Association for Cancer Research 101st Annual Meeting, April 17-21, 2010. Washington DC. Permanent abstract number: 551; Tumor Biology 9. Poster presentation date: April 18, 2010.

114. S.M. Semaan, X.E. Wang, M.R. Emmett, A.G. Marshall, Q.-X. Sang (2010) Identifying glycoproteins in ER+ and ER- human breast cancer tissue samples. American Association for Cancer Research 101st Annual Meeting, April 17-21, 2010. Washington DC. Permanent abstract number: 3309; Tumor Biology 26. Poster presentation date: April 20, 2010.

115. M.H. Constantino, Y. Jin, M.A. Schwartz, Q. Cao, and Q.-X. Sang (2010). Novel mercaptosulfonamide metalloproteinase inhibitors targeting cerebral and cardiovascular diseases and cancer.  American Chemical Society, the 86th Annual Florida Meeting and Exposition (FAME), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 13-15, 2010. Poster presentation.

116. Roycik, M.D.; Cao, Q.; Jin, Y.; Ben, C.; Constantino, M.H.; Bosco, D.B.; Schwartz, M.A.; and Sang, Q.X. (2010) Matrix metalloproteinase inhibitors in vascular wound healing and mesenchymal stem cell differentiation. American Chemical Society, the 86th Annual Florida Meeting and Exposition (FAME), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 13-15, 2010. (Invited Talk).

117. Khamis Z.I., Z.J. Sahab, S.W. Byers, Q.-X. Sang (2010) Leukocyte and endothelium biomarkers in human breast cancer. American Chemical Society, the 86th Annual Florida Meeting and Exposition (FAME), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 13-15, 2010. Poster presentation.

118. Semaan S.M. and Q.-X. Sang (2010) Enhanced basic protein identification in human breast cancer via pre-fractionation prior to 2-DE. American Chemical Society, the 86th Annual Florida Meeting and Exposition (FAME), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 13-15, 2010. Poster presentation.

119. P. A. Stewart, X. Wang, A. G. Marshall, Q.-X. Sang (2010) Characterization of the cellular signaling networks of prostate cancer through phosphoproteome analysis. Invited Talk. Page 3. Atlantic Coast Conference (ACC) Interdisciplinary Forum for Discovery in Life Sciences. Skelton Conference Center, Virginia Tech, Blacksburg, VA. October 3-6, 2010.

120. P. A. Stewart, X. Wang, A. G. Marshall, Q.-X. Sang (2010) Characterization of the cellular signaling networks of prostate cancer through phosphoproteome analysis. Poster Presentation. Page 1. Atlantic Coast Conference  (ACC) Interdisciplinary Forum for Discovery in Life Sciences. Skelton Conference Center, Virginia Tech, Blacksburg, VA. October 3-6, 2010.

121. Sang Q.-X., Y. Jin, Q. Cao, M.H. Constantino, M.D. Roycik, D. Bosco, and M.A. Schwartz (2010) Matrix metalloproteinases in cancer and cerebral and cardiovascular diseases. Georgia State University Biotech Symposium, 2010. Molecular Targeting and Therapeutics. December 3-4, 2010. Atlanta, Georgia. Invited Talk.

122. Q.-X. Sang, Z.I. Khamis, Z.J. Sahab, K.A. Iczkowski (2011) Protein Signatures of Isolated Stromal and Epithelial Cells from Benign and Cancerous Human Prostate Tissues Suggesting a Role of Stroma in Promoting Invasion. DOD Innovative Minds in Prostate Cancer Today (IMPaCT) Conference. March 09 - March 12, 2011. Hilton Orlando, Orlando, FL 32819. Abstract number: PC061396-1803. Poster number: P8-4.

123. K. Decker-Pulice, D. B. Bosco, Q.-X. Sang (2011) Stromelysin Activity in Human Mesenchymal Stem Cells. Honors Chemistry II Laboratory (CHM1051L) poster presentation, Department of Chemistry & Biochemistry, Florida State University. April 22, 2011. Tallahassee, Florida.

124. K. Decker-Pulice, D. B. Bosco, Q.-X. Sang (2011) Stromelysin Activity in Human Mesenchymal Stem Cells. Women in Math, Science, and Engineering (WIMSE) Symposium, poster presentation.  Florida State University. April 2011. Tallahassee, Florida.

125. Q.-X. Sang, Z.I. Khamis, S. Lee, Y.-G. Zhao, H.I. Park, T. Kang, D.R. Hurst, D. A.R. Zorio, Y. Jin, and M.A. Schwartz (2011) Complex roles of human endometase/matrilysin-2 in cancer invasion, progression, and inflammation.  Florida Division of the American Chemical Society, the 87th Florida Annual Meeting and Exposition 2011 (FAME 2011), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 12-15, 2011. (Invited Talk).

126. S. Lee, D. Terry, D. R. Hurst, D.R. Welch, and Q.-X. Sang (2011) Protein Signatures in Human MDA-MB-231 Breast Cancer Cells Indicating a More Invasive Phenotype Following Knockdown of Human Endometase/Matrilysin-2 by siRNA. Florida Division of the American Chemical Society, the 87th Florida Annual Meeting and Exposition 2011 (FAME 2011), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 12-15, 2011. (Poster presentation).

127. Q.-X. Sang, Y. Jin, Q. Cao, M.D. Roycik, D.B. Bosco, S. Lee, M.H. Constantino, D.R. Hurst, Z.I. Khamis, and M.A. Schwartz (2011) Novel Small Molecule Enzyme Inhibitors as Tools to Investigate Biochemical and Cellular Functions of Matrix Metalloproteinases in Cancer, Stroke, and Metabolic Syndrome.  “Regulated Proteolysis of Cell Surface Proteins” Gordon Research Conference, July 10-15, 2011. Davidson College in Davidson, NC, USA. (Session Chair/Discussion Leader, poster presentation).

128. Q.-X. Sang, Z.I. Khamis, S. Lee, Y.-G. Zhao, A. Xiao, H.I. Park, T. Kang, D.R. Hurst, D.A.R. Zorio, Y. Jin, and M.A. Schwartz (2011) Paradoxical Functions of Human Endometase/Matrilysin-2/MMP-26 in Breast and Prostate Cancer Invasion, Progression, Inflammation, and Apoptosis. “Matrix Metalloproteinases” Gordon Research Conference, August 7-12, 2011. Bryant University, Smithfield, RI, USA. (Poster presentation)

129. M.D. Roycik, D.B. Bosco, Y. Jin, Q. Cao, M.A. Schwartz, and Q.-X. Sang (2011) Mercaptosulfonamides: novel tools for exploring the roles of matrix metalloproteinases in adult stem cell proliferation, differentiation, and wound repair. “Matrix Metalloproteinases” Gordon Research Conference, August 7-12, 2011. Bryant University, Smithfield, RI, USA. (Poster presentation)

130. A. N. Wilson, R. Salas, Q.-X. Sang, and A. Guiseppi-Elie (2011) Bioactive Hydrogels Demonstrate Mediated Release of a Chromophore by Chymotrypsin. Abstract and poster presented at Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference. Aug. 15-18, 2011. Fort Lauderdale, FL.

131. D.B. Bosco, M.D. Roycik, Y. Jin, M.A. Schwartz, Q.-X. Sang (2011) Matrix Metalloproteinases as Macromolecular Regulators of Human Mesenchymal Stem Cell Differentiation. Poster presentation number 5. Page 51, NIH NHLBI Symposium on Cardiovascular Regenerative Medicine Program. Natcher Conference Center, NIH Campus, Bethesda, MD. October 4-5, 2011.

132. M.D. Roycik, D.B. Bosco, Y. Jin, Q. Cao, M.A. Schwartz, and Q.-X. Sang (2011). Novel Synthetic Small Molecule Matrix Metalloproteinase Inhibitors and Stem Cell Proliferation and Differentiation. Poster Presentation. NHLBI Symposium on Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, MD. October 4-5, 2011. Poster Presentation.

133. S.M. Semaan, X. Wang, P.A. Stewart, A.G. Marshall, and Q.-X. Sang (2011). Distinctive phosphoprotein profiles in a benign breast tissue, and triple-negative primary and metastatic breast cancer tissues from the same African-American woman by LC-LTQ/FT-ICR mass spectrometry. Poster presentation. Fourth American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. September 18-21, 2011. Washington D.C.

134. P. A. Stewart, X. Wang, S. M. Semaan, A. G. Marshall, Q. X. Sang. Phosphoproteins and bioinformatics of oncogenic pathways of advanced human prostate and breast cancers. 63rd Southeastern Regional Meeting of the American Chemical Society. Poster 293, p70. October 26-29, 2011. Richmond, VA.

135. Q.-X. Sang, P.A. Stewart, X. Wang, S.M. Semaan, and A.G. Marshall (2012) Phosphoprotein signatures and oncogenic pathways of cancers of human breast and prostate. The 2012 FSU Life Sciences Symposium - Found in Translation! Jan. 13, 2012. College of Medicine, Florida State University. Invited Talk.

136. M.H. Constantino, Y. Jin, M.A. Schwartz, and Q.-X. Sang (2012) Novel mercaptosulfonamide metalloproteinase inhibitors targeting prostate cancer and cerebral and cardiovascular diseases. The 2012 FSU Life Sciences Symposium - Found in Translation! Jan. 12-13, 2012. College of Medicine, Florida State University. Poster Presentation.

137. P.A. Stewart, X. Wang, S.M. Semaan, A.G. Marshall, and Q.-X. Sang (2012) Signaling Pathway Discoveries in Cancer Using Phosphoproteomics. The 2012 FSU Life Sciences Symposium - Found in Translation! Jan. 12-13, 2012. College of Medicine, Florida State University. Poster Presentation.

138. S.-Y. Xiong, D.B. Bosco, M.D. Roycik, L. Kang, L.W.K. Chung, and Q.-X. Sang (2012) Comparative Mitochondrial Proteomics of Human ARCaP-Epithelial and ARCaP-Mesenchymal Cells. The 2012 FSU Life Sciences Symposium - Found in Translation! Jan. 12-13, 2012. College of Medicine, Florida State University. Poster Presentation.

139. D.B. Bosco, M.D. Roycik, Y. Jin, M.A. Schwartz, Q.-X. Sang (2012) Mercaptosulfonamides: Novel “Tools” for Exploring the Roles of Matrix Metalloproteinases in Adult Stem Cell Differentiation. Poster Presentation number 2. Page 18, 2nd Annual FSU Life Sciences Symposium: Found in Translation Program. College of Medicine, Florida State University, Tallahassee, FL. January 12-13, 2012.

140. Q.-X Sang, X. Wang, P.A. Stewart, L.W.K. Chung, and A.G. Marshall (2012) Molecular mechanisms and oncogenic pathways revealed by phosphoproteome of advanced human prostate cancer. Poster presentation P-5. 1st Annual Florida Prostate Cancer Research Symposium. Organized by Moffitt Cancer Center and the Advanced Prostate Cancer Collaboration. May 4-5, 2012. Orlando, Florida.  (First place award recipient)

141. Q.-X Sang, X. Wang, S.M. Semaan, P.A. Stewart, L.W.K. Chung, and A.G. Marshall (2012) Phosphoproteins and signal pathways of human prostate cancer and triple-negative breast cancer. Florida Division of the American Chemical Society, the 88th Florida Annual Meeting and Exposition 20121 (FAME 2012), Innisbrook, Palm Harbor, Florida. May 17-19, 2012. (Invited Talk).

142. J. S. Myers, Y. Jin, Q. Cao, J.T. Hare, M.D. Roycik, M.A. Schwartz, and Q.-X.Sang (2012) A cellular blood-brain barrier model for therapeutic testing. Florida Division of the American Chemical Society, the 88th Florida Annual Meeting and Exposition 20121 (FAME 2012), Innisbrook, Palm Harbor, Florida. May 17, 2012. Poster number 5. (First place award recipient)

143. D.B. Bosco, M.D. Roycik, Y. Jin, Q. Cao, M.A. Schwartz, and Q.-X. Sang (2013) Mercaptosulfonamide matrix metalloproteinase inhibitors as tools in models of human disease. The 3rd Annual FSU Life Sciences Symposium, Feb. 14-15, 2013. Page 14. Tallahassee, Florida. Poster presentation.

144. K. Decker-Pulice, D.B. Bosco, and Q.-X. Sang (2013) Matrix metalloproteinase inhibition and fat cell formation. The 3rd Annual FSU Life Sciences Symposium, Feb. 14-15, 2013. Page 16. Tallahassee, Florida. Poster presentation.

145. J. Luks, P.A. Stewart, Q.-X. Sang, and S. Profeta, Jr. (2013) Characterization of matrix metalloproteinase inhibitors using chemical informatics. The 3rd Annual FSU Life Sciences Symposium, Feb. 14-15, 2013. Page 22. Tallahassee, Florida. Poster presentation.

146. Q.-X. Sang (2013) Endometase/matrilysin-2/MMP-26 is a putative human prostate cancer biomarker. 2nd Annual Florida Prostate Cancer Research Symposium. March 22-23, 2013. Orlando, Florida. Organized by Moffitt Cancer Center and Advanced Prostate Cancer Collaboration. Invited Talk, S-9.

147. M.D. Roycik, Y. Jin, D.B. Bosco, M.A. Schwartz, and Q.-X. Sang (2013) Mercaptan-based matrix metalloproteinase inhibitors. Florida Division of the American Chemical Society, the 89th Florida Annual Meeting and Exposition 2013 (FAME 2013), Innisbrook, Palm Harbor, Florida. May 9-11, 2012. (Invited Talk)

Back to the top


Invited Lectures / Seminars

Invited Lectures Presented at Conferences

1. Testicular metalloproteinases; Regulation by hormones and Sertoli peritubular cell interactions, Mid Atlantic Reproductive Biology Conference, University of Virginia. July, 1989.

2. Regulation of human type IV collagenase activity.  The American Cancer Society, Florida Division, Inc., 18th Annual Seminar of Florida Cancer Researchers. 3/25/1995, Orlando, Florida.

3. Biochemical studies of the matrix metalloproteinases (Matrixins).  Invited Biochemistry Faculty Speaker.  Symposium on biomolecular structure and function.  American Chemical Society, Florida Section, 1997 Annual Meeting, May 2 & 3, 1997.  Orlando, Florida.

4. Matrix metalloproteinases and their inhibitors.  Invited Biochemistry Faculty Speaker.   American Chemical Society, Florida Section, 1998 Annual Meeting, May 8 & 9, 1998.  Orlando, Florida.

5. Complex role of matrilysin and type IV collagenases in angiogenesis.  In Vascular Endothelium: Mechanisms of Cell Signaling.  Edited by J.D. Catravas, A.D. Callow, U.S. Ryan.  NATO Science Series.  Series A: Life Sciences. Vol. 308, p. 231. IOS Press. 1999. Amsterdam.  Crete, Greece.  June 28, 1998.

6. Matrixins and metalloproteinase inhibitors in human endothelial cell growth, differentiation, and angiogenesis (Q.X.A. Sang, invited speaker and session chairperson). 5th Biannual International Conference on Angiogenesis: From the Molecular to Integrative Pharmacology.  Crete, Greece.  July 3, 1999.

7. Targeting angiogenesis and cancer invasion with metalloproteinase inhibitors.  2nd International Conference on Protease Inhibitors.  Gainesville, Florida.  December 5, 1999.

8.  Expression, activation, and inhibition of a novel matrix metalloproteinase, endometase.    An International Symposium “Proteinase Inhibitors and Activators” Strategic Targets for Therapeutic Intervention.  University of Oxford, England, UK.  April 18, 2000

8. Endometase, a Novel Matrixin Derived from Human Endometrial Tumor and Endothelium.  NATO Conference on  Vascular Endothelium: Source and Target of Inflammatory Mediators.  NATO Advanced Study Institute.  Crete, Greece.  June 25, 2000.

9. Human disintegrin and metalloproteinase 19, expression, characterization, and potential functions.  International Congress on Membrane-bound Proteolytic Enzymes and Cancer”.  Palermo, Italy.  May 21, 2001.

10. Identification of human adamalysin-19 (disintegrin and metalloproteinase 19) and its putative functions in cardiovascular system and cancer. 6th Biannual International Conference on Angiogenesis: Basic Science and Clinical Developments.  Crete, Greece.  June 28, 2001.

11. Human endometase/MMP-26 may be a novel marker for carcinoma diagnosis and a new target for cancer treatment. 2nd General Meeting of the International Proteolysis Society associated with the International Conference on Protease Inhibitors.  Freising, Germany. November 3, 2001.

12. New metalloproteinases in prostate cancer invasion and angiogenesis. 15th Annual Society for Basic Urologic Research Spring 2002 Meeting.  Orlando, Florida. May 25th, 2002.

13. Mercaptosulfide Inhibitors as Probes for Structure-Function Analysis of Endometase/Matrilysin-2. Fargo Conference on Metalloproteinases, North Dakota State University. Fargo, North Dakota.  Conference Chair, Professor Mukund P. Sibi.  May 30, 2003. 

14. Endometase/Matrilysin-2: Roles in Cancer and Active Site Structure-Function with New MMPIs.  Gordon Research Conference on Matrix Metalloproteinase.  Conference Chairpersons:  Christopher M. Overall and Zena Werb.  Big Sky, Montana.  August 19, 2003. 

15. Metalloproteinases and the Extracellular Matrix in Development, Reproduction, and Cancer. One of the organizers and speakers of the workshop. June 7-10, 2004. Institute of Zoology, Chinese Academy of Sciences, Beijing, P. R. of China. Co-organized by Professors En-Kui Duan and Cheng Zhu, Chinese Academy of Sciences, and Professor Qing-Xiang Amy Sang, Florida State University.  

16. Prostate basal cell layer disruptions and leukocyte infiltration (Endometase/matrilysin-2 in invasion and inflammation). Nov. 6, 2004. Invited speaker. 10th Prouts Neck Meeting on Prostate Cancer. Late Stage Prostate Cancer: a Multidisciplinary Approach. pp. 60.  Nov. 4-7, 2004. Black Point Inn, Prouts Neck, Maine. Organized by the National Cancer Institute and University of Pittsburgh Cancer Institute.

17. Unique Structure and Function of Endometase/Matrilysin-2, a Putative Cancer Biomarker. Invited Talk. American Chemical Society, Florida Section Meeting, Orlando, Florida. May 11, 2007.  Talk number 115.

18. Q.-X. Sang, Z.J. Sahab, Y.-G. Man, R.G. Newcomer (2008) Differential protein expression between microdissected estrogen-receptor positive and negative human breast cancer tissues. Invited Talk. American Chemical Society, Florida Section FAME Meeting, Orlando, Florida. May 9, 2008. Talk number 58.

19. Q.-X. Sang (2008) Protein Biomarkers of Human Breast and Prostate Cancer Invasion and Progression at the Interface of Benign and Malignant Tumors. BIT’s Annual World Cancer Congress 2008. Invited talk at the session 32 on Cancer Invasion and Metastasis. Shanghai, China. June 13, 2008.

20. Q.-X. Sang (2009) Metzincin clan of metalloproteinases as therapeutic targets. American Chemical Society 237th National Meeting & Exposition. Invited talk, the Recent Developments in Metalloprotease Inhibitors Session, Division of Medicinal Chemistry. March 23, 2009. Paper ID: 1246333 and paper number: 140. Salt Lake City, UT. March 22-March 27.

21. Q.-X. Sang, Y. Jin, S. Lee, Q. Cao, C. Ben, M.D. Roycik, B. Qi, and M.A. Schwartz (2009) Metzincin metalloproteases and their functions in cancer, stroke, and inflammatory diseases. American Chemical Society, the 85th Annual Florida Meeting and Exposition (FAME), Orlando, Florida. May 15, 2009. Invited Talk. Abstract number 54.

22. M.D. Roycik, Q. Cao, Y. Jin, D.B. Bosco, M.A. Schwartz, Q.-X. Sang (2009) Exploring Roles of Matrix Metalloproteinases in Human Mesenchymal Stem Cell Differentiation with Novel Synthetic Inhibitors. Invited Talk. Page 22, 2nd Southeast Stem Cell Consortium Workshop Program. Paul D. Coverdell Center, University of Georgia, Athens, GA. October 15-16, 2010.

23. Q.-X. Sang. Challenges of identifying biomarkers of human cancer invasion and metastasis. Georgia State Biotechnology Symposium, 2009. Advances in Cancer Research:  Biomarker Detection – Epigenetic Gene Regulation. Invited Talk. November 23-24, 2009. Atlanta, Georgia.

24. Roycik, M.D.; Cao, Q.; Jin, Y.; Ben, C.; Constantino, M.H.; Bosco, D.B.; Schwartz, M.A.; and Sang, Q.X. (2010) Matrix metalloproteinase inhibitors in vascular wound healing and mesenchymal stem cell differentiation. American Chemical Society, the 86th Annual Florida Meeting and Exposition (FAME), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 13-15, 2010. (Invited Talk).

25. Sang Q.-X., Y. Jin, Q. Cao, M.H. Constantino, M.D. Roycik, D. Bosco, and M.A. Schwartz (2010) Matrix metalloproteinases in cancer and cerebral and cardiovascular diseases. Georgia State University Biotech Symposium, 2010. Molecular Targeting and Therapeutics. December 3-4, 2010. Atlanta, Georgia. Invited Talk.

26. Q.-X. Sang, Z.I. Khamis, S. Lee, Y.-G. Zhao, H.I. Park, T. Kang, D.R. Hurst, D. A.R. Zorio, Y. Jin, and M.A. Schwartz (2011) Complex roles of human endometase/matrilysin-2 in cancer invasion, progression, and inflammation.  Florida Division of the American Chemical Society, the 87th Florida Annual Meeting and Exposition 2011 (FAME 2011), Innisbrook Resort and Gulf Club, Palm Harbor, Florida. May 12-15, 2011. (Invited Talk).

27. Q.-X. Sang, P.A. Stewart, X. Wang, S.M. Semaan, and A.G. Marshall (2012) Phosphoprotein signatures and oncogenic pathways of cancers of human breast and prostate. The 2012 FSU Life Sciences Symposium - Found in Translation! Jan. 13, 2012. College of Medicine, Florida State University. Invited Talk

28. Q.-X Sang, X. Wang, S.M. Semaan, P.A. Stewart, L.W.K. Chung, and A.G. Marshall (2012) Phosphoproteins and signal pathways of human prostate cancer and triple-negative breast cancer. Florida Division of the American Chemical Society, the 88th Florida Annual Meeting and Exposition 2012 (FAME 2012), Innisbrook, Palm Harbor, Florida. May 17-19, 2012. (Invited Talk).

29. Q.-X. Sang (2013) Endometase/matrilysin-2/MMP-26 is a putative human prostate cancer biomarker. 2nd Annual Florida Prostate Cancer Research Symposium. March 22-23, 2013. Orlando, Florida. Organized by Moffitt Cancer Center and Advanced Prostate Cancer Collaboration. Invited Talk, S-9.

30. M.D. Roycik, Y. Jin, D.B. Bosco, M.A. Schwartz, and Q.-X. Sang (2013) Mercaptan-based matrix metalloproteinase inhibitors. Florida Division of the American Chemical Society, the 89th Florida Annual Meeting and Exposition 2013 (FAME 2013), Innisbrook, Palm Harbor, Florida. May 9-11, 2012. (Invited Talk)

 

Invited Lectures Presented at Academic Institutions and Companies

1. Testicular metalloproteinases; Regulation by hormones, mesenchymal-epithelial cell interactions, and ECM components.  Biochemistry and Molecular Biophysics Seminar.  The Florida State University.  Host: Professor William Marzluff.  October 16, 1990.

 

2. Identification and regulation of type IV collagenase in testicular cell culture. Department of Biological Sciences Colloquium.  The Florida State University.  Host: Professor Timothy Moerland.  January 23, 1992.

 

3. Activation of human neutrophil gelatinase (type IV collagenase)--is there an internal human matrix metalloproteinase activation cascade?  Biochemistry and Structural Biology Seminar.  The Florida State University.  Host: Professor Robley J. Light.  October 27, 1992.

 

4. Activation mechanisms of human matrix metalloproteinases; regulation of the activity of human neutrophil gelatinase/type IV collagenase.  Biochemistry and Physical Biochemistry Seminar.  Universidad Autonoma Metropolitana de Iztapalape, Mexico City, Mexico. June 3, 1993.

 

5. Activation of human matrix metalloproteinase-9 (Gelatinase B),  Seminar at National Institutes of Health, U.S. Department of Health & Human Services, Bethesda, Maryland.  February 23, 1994.  Host: Dr. Hynda K. Kleinman, Chief of Cell Biology Section, NIDR, NIH.

 

6. Matrix metalloproteinases in cancer cell invasion and metastasis, Biochemistry/Structural Biology Seminar at the Florida State University, September 6, 1994.  Host:  Dr. Michael Chapman.

 

7. Activation mechanisms of matrix metalloproteinases, Biochemistry/Structural Biology Seminar at the Florida State University, March 7, 1995.  Host:  Dr. Penny Gilmer.

 

8. Human breast cancer cell-fibroblasts interaction induced membrane-type matrix metalloproteinase-1 (MT1-MMP) production and gelatinase activation.  Department of Biochemistry, Faculty of Chemistry, University of Bielefeld, Germany. July 8, 1996.  Host: Professor and Dr. Harald Tschesche.

 

9. Activation of human neutrophil gelatinase B and fibroblast gelatinase A by matrilysin and human fibroblast collagenase; Human breast cancer cell-fibroblasts interaction induced membrane-type matrix metalloproteinase-1 (MT1-MMP) production and gelatinase activation.  Hospital Rechts der Isar, Technical University, Munich, Germany. July 12, 1996.  Host: Professor and Dr. Manfred Schmitt.

 

10. Regulation of Matrix Metalloproteinases, from Corneal Ulcer to Angiogenesis.  The Schepens Eye Research Institute, Harvard Medical School.  July 26, 1996.  Host: Dr.  Karl Hecker.

 

11. Regulation of Matrix Metalloproteinases.  Department of Chemistry, Florida State University.  October 18, 1996.  Host: Professor Randy Rill.

 

12. Novel Matrix Metalloproteinases, Implications in Metamorphosis and Metastasis.  Karmanos Cancer Institute Prostate Initiative, Wayne State University, Detroit, Michigan.  October 23, 1996.  Host:  Professor Kenneth V. Honn.

 

13. Biochemical Characterization of Collagenases, Potential Roles in Development and Cancer.  Department of Anatomy, Iowa Cancer Center, University of Iowa, Iowa City, Iowa.  November 7, 1996.  Host:  Dr. Mary Hendrix, Professor and Head.

 

14. Activation, Inhibition, and Substrate Specificities of Gelatinases and Collagenases.  Department of Basic Sciences, Northwestern University Dental and Medical School, Chicago, IL.  January 23, 1997.  Host, Professor Saryu N. Dixit.

 

15. The Collagenase Family in Metamorphosis and Metastasis. Medical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.  February 27, 1997.  Host: Professor Anthony L. Mescher.

 

16. Antibody Production and Characterization of a Breast Cancer Surface Metalloproteinase.  Department of Cell Biology and Anatomy, Breast Cancer Research Program and Tumor Cell Biology Program, University of Miami Medical School, Miami, Florida.  May 20, 1997.  Host, Professor Lilly Y.W. Bourguignon.

 

17. The Matrixin Family of Metalloenzymes and Their Inhibitors.  Department of Chemistry, University of Central Florida, Orlando, Florida.  January 12, 1998.  Host, Professor Otto Phanstiel.

 

18. Matrixins and Metalloproteinase Inhibitors in Cancer and Cardiovascular Disease.  Department of Chemistry and Biochemistry, College of Charleston, Charleston, South Carolina.  November 5, 1998.  Host, Professor James P. Deavor.

 

19. Biochemical Investigations of Metalloproteinases in Angiogenesis and Reproduction.  National Research Institute for Family Planning and World Health Organization Collaborating Center for Research in Human Reproduction, Beijing, P.R. of China.  November 23, 1998.  Host,  Professor Bilian Xiao.

 

20. Biochemical Characterization of Matrixins and Metalloproteinase Inhibitors in Cancer and Angiogenesis.  State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, P.R. of China.  November 24, 1998.  Host, Professor Enkui Duan.

 

21. Activation, Inhibition, and Substrate Specificities of Metalloproteinases and Their Role in Cancer and Angiogenesis.  Department of Chemistry, University of South Florida.  February 11, 1999.  Host, Professor Li-June Ming.

 

22. Targeting Collagen-degrading Matrixins in Angiogenesis and Cancer.  Human Genome Sciences, Inc.  Rockville, Maryland.  September 1, 1999.  Host, Dr. Jian Ni.

 

23. Extracellular Matrix Degrading Metalloproteinases in Development and Angiogenesis.  Department of Cell Biology, Georgetown University Medical Center, Washington D.C.  September 2, 1999.  Hosts, Professors Martin Dym and Carlos Suarez-Quian.

 

24. Identification and Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial Tumor. Max-Planck-Institute for Biochemistry, Martinsried, Germany. June 23, 2000. Host, Professor and Dr. Wolfram Bode.

 

25. Cloning, Expression, and Enzymatic Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial Tumor.  Department of Biochemistry, Faculty of Chemistry, University of Bielefeld, Germany. July 3, 2000.  Host: Professor and Dr. Harald Tschesche.

 

26. Discovery, Expression, and Biochemical Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial Tumor. Department of Surgery and Medicine, University of Tübingen, Germany.  July 5, 2000.  Host:  Dr. Silvia Wagner.

 

27. Discovery and Biochemical Studies of Human Cancer Endometase (Matrix Metalloproteinase-26).  Department of Chemistry, University of Tennessee at Chattanooga.  Chattanooga, Tennessee.  September 1, 2000.  Host:  Professor Kyle Knight.

 

28. Endometase, a Novel Matrix Metalloproteinase (MMP-26) Derived from Human Cancers. Provid Research (Division of Praecis Pharmaceuticals Inc), Piscataway, New Jersey.  November 1, 2000.  Host:  Dr. Chris Self.

 

29. Discovery and Biochemical Studies of a Novel Metalloproteinase in Cancer.   Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, Florida. November 17, 2000.  Host, Professor Russell G. Kerr.

 

30. New Zinc Metalloproteinases and the Inhibitors in Development, Angiogenesis and Metastasis.  Department of Chemical Engineering, FAMU-FSU College of Engineering, Tallahassee, Florida.  September 20, 2001.  Host, Professor Steve Gibbs.

 

31. New Metalloproteinases in Human Endometrial, Breast, and Prostate Cancer Cells and Rationally Designed Novel Metalloproteinase Inhibitors.  Institute of Experimental Oncology and Therapeutics, Technical University of Munich, Munich, Germany.  October 29, 2001.  Host, Dr. Achim Krüger. 

 

32. Molecular, Enzymatic, and Functional Investigations of Endometase, a New Carcinoma Matrix Metalloproteinase. Biomolecular Research Center and Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida.  November 19, 2001.  Host, Professor Antonis S. Zervos.

 

33. New Metalloproteinases in Cancer Progression and Angiogenesis.  Department of Pathology and Laboratory Medicine Research Seminar. University of Cincinnati. Cincinnati, Ohio.  February 21, 2002. Host, Professor Joan Cook-Mills.

 

34. Novel Metalloproteinases in Cancer.  Department of Chemistry and Biochemistry, Florida State University. Tallahassee, Florida. March 29, 2002.  Host, Professor Martin A. Schwartz and the Departmental Faculty. 

 

35. How to Stop the Spread of Cancer?  Department of Chemistry and Biochemistry, Florida State University. Tallahassee, Florida. April 15, 2002.  Host, Ms. Sandy Scheer and the Departmental Staff Members.

 

36. Ideas for Stopping Breast and Prostate Cancer Invasion.  A Story of Discovering Human Endometase.  American Cancer Society Luncheon and Seminar. Panama City, Florida. June 25, 2002.  Host, Mr. Anthony Barclay, American Cancer Society.

 

37. New Ideas on How to Identify and Block Invasive Cancers. American Cancer Society Luncheon and Seminar. Tallahassee, Florida. August 22, 2002.  Host, Mr. Anthony Barclay, American Cancer Society.

 

38. Novel Functions of Matrix Metalloproteinases and Adamalysins in Cancer and Cardiovascular Diseases.  Mayo Clinic, Jacksonville, Florida.  March 11-23, 2003.  Host, Lawrence A. Solberg Jr., Ph.D., M.D.

 

39. Matrilysin-2/Endometase/MMP-26 in Human Cancer and Reproduction.  Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee.  April 1, 2003.  Host, Professor Lynn M. Matrisian, Ph.D.

 

40. Endometase/matrilysin-2 in cancer and reproduction.  Neuroscience Colloquium, Florida State University. October 22, 2003.  Host: Professor Karen J. Berkley, Ph.D.

 

41. Metalloproteinases in cancer and cardiovascular Diseases.  Mayo Clinic, Jacksonville, Florida.  January 30, 2004.  Host, Robert Smallridge, M.D.

 

42. Discovery and structural-functional properties of endometase/matrilysin-2, a potential invasion marker. Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana. May 10, 2004. Host, Professor Shahriar Mobashery, Ph.D.

 

43. Biology and Pathology of Matrix Metalloproteinases (MMPs) and Extracellular Matrix (ECM). Institute of Zoology, Chinese Academy of Sciences, Beijing, P.R. of China. June 7, 2004. Hosted by Professor En-Kui Duan, Ph.D.

 

44. MMPs and ADAMs in Heart Development and Cardiovascular Diseases. Institute of Zoology, Chinese Academy of Sciences, Beijing, P.R. of China. June 8, 2004. Hosted by Professor Cheng Zhu, Ph.D.

 

45. MMPs in Human Breast Cancer. Institute of Zoology, Chinese Academy of Sciences, Beijing, P.R. of China. June 9, 2004. Hosted by Professor En-Kui Duan, Ph.D.

 

46. New Hopes for MMPs as Therapeutic Targets for Cancer, Cardiovascular, and other Diseases. Institute of Zoology, Chinese Academy of Sciences, Beijing, P.R. of China. June 10, 2004. Hosted by Professor Cheng Zhu, Ph.D.

 

47. Endometase/matrilysin-2 in human breast and prostate cancer invasion. Department of Biological Sciences and College of Medicine, Tsinghua University, Beijing, P. R. of China. June 24, 2004. Host, Professor Duanqing Pei, Ph.D.

 

48. The significance of myoepithelial cell layer disruption in human breast cancer invasion; a paradigm shift from the “protease-centered” hypothesis. Department of Biological Sciences and College of Medicine, Tsinghua University, Beijing, P. R. of China. June 25, 2004. Host, Professor Duanqing Pei, Ph.D.

 

49. Factors involved in the initiation of human breast and prostate cancer invasion. National Research Institute of Family Planning, Beijing, P.R. of China. June 29, 2004. Host, Professor Meng-Chun Jia, M.D.

 

50. Metalloproteases and non-protease factors in early stages of tumor invasion; new hypotheses on the “mutated stem cells” and cancer drug resistance. Van Andel Research Institute in Grand Rapids, Michigan. October 27, 2004. Host: Professor James Resau, M.D. & Ph.D.

 

51. Inflammation, Cancer Stem Cells, and Tumor Invasion. Institute of Zoology, Chinese Academy of Sciences, Beijing, May 20th, 2005. Host:  Professor Cheng Zhu.

 

52. A story of endometase/ matrilysin-2/MMP-26. Institute of Zoology, Chinese Academy of Sciences, Beijing, May 25th, 2005. Host: Professor En-Kui Duan.

 

53. Lessons from successful and failed grant applications-tips on how to prepare better grant applications. Institute of Zoology, Chinese Academy of Sciences, Beijing, May 26th, 2005. Host: Professor Yan-Ling Wang.

 

54. Leukocyte infiltration, mutated cancer stem cells, and tumor progression. The Key Laboratory of Pathology and School of Medicine, Jilin University, Changchun, May 31, 2005. Host: Professor Wei Li.

 

55. Endometase/matrilysin-2 biochemistry and putative roles in cancer. The Key Laboratory of Enzyme Engineering and Enzymology, Jilin University Changchun, June 2, 2005. Host: Professor Xuexun Fang.

 

56. Lessons and practical tips on how to prepare compelling grant applications and manuscripts. College of Life Sciences, Jilin University Changchun, June 3, 2005. Host: Professor Xuexun Fang.

 

57. A new paradigm on the initiation of human breast and prostate cancer invasion. Department of Biology, Georgia State University, Atlanta, Georgia. Oct. 7, 2005. Host: Professor Zhi-Ren (Luis) Liu, Ph.D.

 

58. Molecular characterization of human endometase/matrilysin-2, a putative biomarker for carcinomas and embryo implantation. Laboratory of Gene Regulation and Development, National Institute Child Health and Human Development (NICHD), National Institutes of Health (NIH). Bethesda, Maryland. June 13, 2006. Host:  Dr. Yun-Bo Shi.

 

59. Matrix metalloproteinase-26 in human prostate and breast cancers, paradoxical roles in invasion and survival. Center for Prostate Disease Research, Walter Reed Army Medical Center, Uniformed Services University of the Health Sciences, Department of Defense. June 14, 2006. Hosts: Drs. Albert Dobi, Chunling Gao, and Kee-Hong Kim.

 

60. Endometase/matrilysin-2, biomarker discovery, and new ideas on human breast and prostate cancer apoptosis and invasion. Department of Pathology and Laboratory of Medicine. University of Kansas Medical Center, Kansas City, Kansas. August 17, 2006. Host: Professor and Doctor Patricia A. Thomas.

 

61. Biomarker and enzyme inhibitor discovery for targeting human breast and prostate cancer invasion using multidisciplinary approaches.  Department of Chemistry and Biochemistry, Montclair State University, Montclair, New Jersey. March 8, 2007. Host: Dr. Jeffrey H. Toney, Sokol Professor and Chairperson.

 

62. Discovery and Biochemical Characterization of Human Endometase/Matrilysin-2, a Putative Biomarker of Breast and Prostate Cancers. Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL. March 16, 2007. Host: Professor Timothy Cross.

 

63. Human Endometase/Matrilysin-2 as an Early Cancer Biomarker and Role of Leukocytes in Triggering Cancer Invasion. Oncology Research, MultiMedica Scientific and Technological Pole in Via Fantoli 16/15, Milan, Italy. June 1, 2007. Host: Professor and Dr. Adriana Albini.

 

64. Human Matrix Metalloproteinase-26 and Ideas on Initiation of Breast and Prostate Cancer Invasion. The Center of Experimental Cancer Research in the University of Liège, Liège, Belgium. June 12, 2007. Host: Professor Agnès Noel.

 

65. Endometase/Matrilysin-2 as a Biomarker for Preinvasive Cancers of Human Breast and Prostate. Rega Institute for Medical Research, Catholic University of Leuven, Leuven, Belgium. June 13, 2007. Host:  Professor and Dr. Ghislain Opdenakker.

 

66. Human MMP-26 and MMP-9, myoepithelial and basal cell layer disruption, and breast and prostate cancer invasion. Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris, Creteil, Paris, France. June 18, 2007. Host: Professor Suzanne Menashi.

 

67. Endometase/Matrilysin-2/MMP-26 and other Biomarkers in Human Breast and Prostate Cancer Invasion and Progression. Department of Pathology, Cell Biology, and Pharmacology/Toxicology, University of Alabama at Birmingham, Birmingham, Alabama. March 12, 2008. Hosts: Dr. Douglas R. Hurst and Professor Danny R. Welch, Leonard H. Robinson Chaired Professor of Pathology.

 

68. Endometase/Matrilysin-2 as a Potential Biomarker for Early Stage of Human Breast and Prostate Cancer. Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland. July 16, 2008. Host: Professor Chen-Yong Lin.

 

69. Matrix metalloproteinases and their inhibitors in cancer and cardiovascular and cerebral vascular diseases. Department of Neurology, University of New Mexico, Albuquergue, New Mexico. August 14, 2009. Host: Professor and Dr. Gary Rosenberg, Chairman and Professor of Department of Neurology.

 

70. Human Endometase/Matrilysin-2/MMP-26, a Putative Cancer Biomarker. Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington DC. February 23, 2010. Host:  Professor and Dr. Martin Dym.

 

71. Matrix Metalloproteinases and Their Inhibitors, and Role in Cancer, Stroke, and Cardiovascular Diseases. Department of Chemical and Biomolecular Engineering and Department of Bioengineering, College of Engineering and Science, Clemson University, Clemson, South Carolina. March 11, 2010. Host:  Professor Anthony Guiseppi-Elie.

 

72. Matrix Metalloproteinases in Cancer, Stroke, and Stem Cell Differentiation.  Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas. October 18, 2010. Host:  Professor Pengyu Ren.

 

73. Metalloproteinases, Enzyme Inhibitors, and Putative Protein Cancer Biomarkers. Department of Biomedical Sciences, Florida State University College of Medicine. February 29, 2012. Host: Professor Michael Blaber.

 

74. Protein Biomarker and Drug Discovery in Human Cancers of Prostate and Breast. Department of Biochemistry & Cancer Biology, Meharry Medical College, Nashville, TN. March 16, 2012. Host:  Professor Zhenbang Chen

75. Human Cancer Biomarker Discovery and Health Disparity, Chemical & Biomedical Engineering Seminar, College of Engineering, FAMU-FSU, January 11, 2013. Host: Professor Yan Li.

 

76. Structure and function of human endometase/matrilysin-2/MMP-26, a putative cancer biomarker. Sun Yat-sen University Cancer Center. Guangzhou, P.R. of China. July 8, 2013. Host, Professor Chao-Nan (Miles) Qian, MD, PhD.

 

77. Phosphoprotein signatures and oncogenic signal pathways of human prostate cancer and triple-negative breast cancer. Sun Yat-sen University Cancer Center. Guangzhou, P.R. of China. July 8, 2013. Host, Professor Chao-Nan (Miles) Qian, MD, PhD.



Back to the top


Honors and Awards

Georgetown University Medical School Competitive Graduate Fellowship, 1986 1989.

Student Travel Award, American Society for Cell Biology, 1989.

Individual National Research Service Award from Public Health Service, National Institutes of Health Individual Postdoctoral Fellowship (F32, NIH, NIGMS 14336), May 1992-September 1993.

Henry F. Abel Research Award, American Caner Society, the Florida Division, 1994-1995.

Elsa U. Pardee Foundation Award, 1995.

The RGK Foundation Award, 1994-1995.

The Gustavus and Louise Pfeiffer Foundation Award, 1996.

Robert J. Boucek, M.D. Research Award, to the highest merit rated researcher for the American Heart Association, Florida Affiliate, 1996-1997.

Elsa U. Pardee Foundation Award, 1997.

The Gustavus and Louise Pfeiffer Foundation Award, 1997.

First-Year Assistant Professor Award, Florida State University, Council on Research and Creativity (CRC). 1997-1998.

FIRST Award (R29). National Cancer Institute, National Institutes of Health. 1998-2003.

Travel Award from NATO Advanced Study Institute for attending a Conference on Vascular Endothelium: Mechanisms of Cell Signaling, Crete, Greece. June 20-29, 1998.

The Gustavus and Louise Pfeiffer Foundation Award, 1999.

Elsa U. Pardee Foundation Award, 2000.

Pilot Award, American Cancer Society, Florida Division, 2001-2002.

Nominated for “The Camille Dreyfus Teacher-Scholar Award” by FSU, 2001.

Florida State University Program Enhancement Grant Award, 2001-2003.

U.S. Army Prostate Cancer Research Program New Investigator Award, Department of Defense, 2002-2005.

Developing Scholar Award, Florida State University, 2003-2004.

Faculty Merit Ranking #1, Department of Chemistry and Biochemistry, FSU, 2003-2004.

Nominated for a membership of the National Academy of Sciences, USA by Professor Michael Kasha, 2003-2004.

Faculty Senator, Florida State University. 2003-2004, 2004-2005.

Faculty Merit Ranking #2, Department of Chemistry and Biochemistry, FSU, 2004-2005.

Nominated for a Graduate Faculty Mentor Award by graduate students, FSU, 2004-2005.

Nominated for a University Teaching Award by undergraduate students, FSU, 2004-2005.

Elsa U. Pardee Foundation Award, 2005.

Susan G. Komen Breast Cancer Foundation Research Award, 2005-2008.

Distinguished Faculty, Florida State University, 2006-2007.

Distinguished Lecturer, Center for Prostate Disease Research, Walter Reed Army Medical Center, Uniformed Services University of the Health Sciences, Department of Defense. 2006.

Member, The Deutscher Akademischer Austausch Dienst (DAAD, German Academic Exchange Service) Research Tour 2006, “Science in Germany: New Developments in Higher Education, Interdisciplinary Cooperation and Industrial Application” December 3rd to December 9th, 2006.

Faculty Senator Alternate, Florida State University. 2007-2011.

Exploration-Hypothesis Development Award, U.S. Army Prostate Cancer Research Program (PCRP), Department of Defense, 2007-2009.

Initiated into the Honor Society of Phi Kappa Phi, the nation's oldest, largest, and most selective all-discipline honor society. Permanent member. April 5, 2007-present.

Faculty Merit Ranking #1, Department of Chemistry and Biochemistry, FSU, 2006-2007.

Florida State University Council on Research and Creativity (CRC) Planning Grant. 2007-2008.

GAP award from the Florida State University, 2008-2009.

Innovator Award, Florida State University, 2009.

Florida Breast Cancer Research Coalition Foundation Award. 2009.

NIH R21 Award, National Institute of Neurological Disorders and Stroke, NIH. Co-PI with Professor Gary Rosenberg. 2009-2011.

NIH R01 Award, National Institute of Neurological Disorders and Stroke, NIH. Co-PI with Professor Gary Rosenberg. 2009-2011.

GAP award from the Florida State University, 2010-2011.

Florida Department of Health James & Esther King Biomedical Research Program Technology Transfer Feasibility Award, 2011-2012.

Graduate Faculty Mentor Award, 2010-2011, Florida State University

Innovator Award, Florida State University, 2011.

Florida Department of Health James & Esther King Biomedical Research Program Technology Transfer Feasibility Award, 2011-2012.

Florida State University Council on Research and Creativity (CRC) Planning Grant. 2011-2012.

Elsa U. Pardee Research Foundation Award for Human Breast Cancer Research, 2012.

GAP Award from the Florida State University, 2012-2013.

Innovator Award, Florida State University, 2012.

Florida State University Council on Research and Creativity (CRC) Committee on Faculty Research Support (COFRS) Award, 2013.


Professional Memberships

Associate Member, American Society for Cell Biology, 1988 1992

Member, American Society for Cell Biology, 1992-1997

Associate Member, Sigma Xi, the Scientific Research Society, 1989 1991

Member, Sigma Xi, the Scientific Research Society, 1991-1992

Member of American Association for the Advancement of Science, 1995-2002, and 2011-present

Member of the International Proteolysis Society, 2001-2003

Member of American Society for Biochemistry and Molecular Biology, 1998-2008

Member of American Association for Cancer Research (AACR), 2001-present

Member of Women in Cancer Research, AACR, 2005-present

Member of Chemistry in Cancer Research Working Group, AACR, 2006-present

Member of Tumor Microenvironment, AACR, 2007-present

Member of Cancer Immunology Working Group, AACR, 2007-present

Member of Minority in Cancer Research Working Group, AACR, 2008-present

Member of American Chemical Society, 2008-present

Editorial Board Member:  Journal of Cancer, 2010-present

Member/Reviewer of Grant Peer Review Panels/Study Sections

1. Scientist Reviewer of a grant Peer Review Panel (Cell and Tissue Biology #1) of the U.S. Army Medical Research and Development Command, Breast Cancer Research Program, U.S. Department of Defense.  February 20-22, 1994.  Arlington, Virginia.

2. Scientist Reviewer of a grant Peer Review Panel (Panel #2), National Action Plan on Breast Cancer, Office on Women's Health and National Cancer Institute, NCI, NIH, PHS.  July 19-20, 1995, Washington D.C.

3. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  September 4-7, 1996.  Arlington, Virginia.

4. Mail Reviewer for the 1993 Breast Cancer Research Program Awards Assessment and Monitoring Project, U.S. Army Medical Research and Materiel Command, FY93/94 Breast Cancer Research Program, Annual/Final Review.  American Institute of Biological Sciences.  Review 1-2 Progress/Final reports/month, 1996-2000.

5. Grant Reviewer for the Israel Science Foundation, The Israel Academy of Sciences and Humanities, Jerusalem, Israel.  1997-present.

6. Scientist Reviewer of a grant Peer Review Panel (Cell Biology #2) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  September 15-17, 1997. Vienna, Virginia.

7. Scientist Reviewer of a Review Panel for the Susan G. Komen Breast Cancer Foundation, the Basic, Clinical and Transnational Research Panel. July-August, 1998.

8. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  August 29-31, 1999.  Tyson Corners, Vienna, Virginia.

9. Scientist Reviewer of a Review Panel for the Susan G. Komen Breast Cancer Foundation, the Basic, Clinical and Transnational Research Panel Reviewing 1998 Grant Extension Applications.  Feb. 28, 2000.

10. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  August 13-15, 2000.  Tyson Corners, Vienna, Virginia.

11. Grant reviewer for British national funding agency, Medical Research Council, United Kingdom. 2002-present.

12. Grant reviewer for the American Chemical Society, the Petroleum Research Fund (ACS-PRF AC proposals) and Research Cooperation. 2002-present.

13. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  August 11-13, 2002.  Tyson Corners, Vienna, Virginia.

14. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  July 27-29, 2003.  Reston, Virginia.

15. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Prostate Cancer Research Program, U.S. Department of Defense.  April 18-20, 2004.  Lansdowne, Virginia.

16. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  July 18-20, 2004.  Reston, Virginia.

17. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Prostate Cancer Research Program, U.S. Department of Defense.  April 10-12, 2005.  Vienna, Virginia.

18. Scientist Reviewer of a grant Peer Review Panel (Cell Biology #3) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense.  August 7-9, 2005.  Reston, Virginia.

19. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, Concept Award mechanism. U.S. Department of Defense.  Feb.14-March 27, 2006, online web-based review.

20. Scientist Reviewer of a grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Prostate Cancer Research Program, U.S. Department of Defense.  June 14-16, 2006.  Reston, Virginia.

21. Scientist Reviewer of a grant Peer Review Panel (Synergistic Idea Award #3) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  March 18-20, 2007.  Reston, Virginia.

22. Scientist Reviewer of a grant Peer Review Panel (Molecular Signaling, Basic Cell and Molecular Biology, #5A), the American Heart Association, Southern/Ohio Valley #5A. April 23-24, 2007, Tampa, Florida.

23. Scientist Reviewer of a grant Peer Review Panel (Synergistic Idea Development Award #1) of the U.S. Army Medical Research and Materiel Command, Prostate Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  August 12-14, 2007.  Alexandria, Virginia.

24. Scientist Reviewer of a Grant Peer Review Panel (Pathobiology #2) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  July 16-18, 2008.  Reston, Virginia.

25. Scientist Reviewer of a Grant Peer Review Panel (Targeted Therapies 2) of the Susan G. Komen for the Cure Breast Cancer Research Grants Program. November 20-21, 2008. Chantilly, Virginia.

26. Scientist Reviewer of a Grant Peer Review Panel, Basic Cell and Molecular Biology 4, 2009 Spring Region 1, American Heart Association. Teleconference on April 27, 2009.

27.  Scientist Reviewer of a Grant Peer Review Panel (Training Grants: Molecular Biology and Genetics – B: MBG-B) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  May 3-5, 2009.  Herndon, Virginia.

28. Scientist Reviewer of Prostate Cancer Foundation of Australia Research Grant Program. 2009-

29. Scientist Reviewer of a Grant Peer Review Panel (Targeted Therapies 3) of the Susan G. Komen for the Cure Breast Cancer Research Grants Program. November 3-4, 2009. Dallas, Texas.

30. Scientist Reviewer of the Online Pre-Pathobiology B Grant Peer Review Panel, 2010 Prostate Cancer Research Program,  U.S. Department of Defense, Congressionally-Directed Medical Research Program. March-April 2010.

31. Scientist Reviewer of a Grant Peer Review Panel (Pathobiology #3) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  June 23-25, 2010.  Reston, Virginia.

32. Grant Reviewer for the National Science Foundation, Chemistry of Life Processes. 2010-present.

33. Online Scientist Reviewer, Pre-application - Pathobiology-2 (Pre-PBY-2), and Pathobiology-1 (Pre-PBY-1) 2011 Prostate Cancer Research Program. The Department of Defense Congressionally Directed Medical Research Programs (CDMRP). June-July 2011.

34. Scientist Reviewer of a Grant Peer Review Panel (Pathobiology #1) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  October 16-18, 2011.  Reston, Virginia.

35. Online Scientist Teleconference Reviewer, 2011 BCRP Adhoc-1 panel, 2011 Breast Cancer Research Program. The Department of Defense Congressionally Directed Medical Research Programs (CDMRP). March 2012.

36. Online Scientist Reviewer, 2012 PCRP Preapplication-Pathobiology-1 and Physical Imaging Panels.  2012 Prostate Cancer Research Program. The Department of Defense Congressionally Directed Medical Research Programs (CDMRP). April –June 2012.

37. Scientist Reviewer of a Grant Peer Review Panel (Pathobiology) of the U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program, U.S. Department of Defense, Congressionally-Directed Medical Research Program.  October 10-12, 2012.  Reston, Virginia

Reviewer of Scientific Articles

1. Reviewer for Protein Science, a publication of the Protein Society.  1997-present.

2. Reviewer for The Journal of Biological Chemistry by the American Society for Biochemistry and Molecular Biology, Inc.  1998-present.

3. Reviewer for Cancer Research, Academic Press.  1998-present.

4. Reviewer for The American Journal of Pathology, Cellular and Molecular Biology of Disease.  The official publication of the American Society for Investigative Pathology. 1998-present.

5. Reviewer for The American Journal of Physiology: Cell Physiology. 1998-present.

6. Reviewer for the British Journal of Cancer, The Clinical and Scientific Journal of the Cancer Research Campaign.  1998-present.

7. Reviewer for Biology of Reproduction, 2000-present.

8. Reviewer for Developmental Dynamics, 2000-present.

9. Reviewer for The Journal of Organic Chemistry,  2000-present.

10. Reviewer for Investigative Ophthalmology and Visual Science, 2001-present.

11. Reviewer for Journal of the National Cancer Institute, 2001-present.

12. Reviewer for the Journal of Molecular Biology Reports (MOLE), Kluwer academic publishers, 2002-present.

13. Reviewer for the Journal of Molecular Biology, 2002-, Elsevier Science publishers.

14. Reviewer for Cell Research, 2002-present.

15. Reviewer for Clinical and Experimental Metastasis, Official Journal of the Metastasis Research Society, 2002-present.

16. Reviewer for the Journal of Medicinal Chemistry, an Official Journal of the American Chemical Society. 2002-present.

17. Reviewer for FEBS Letters, Federation of European Biochemical Societies. Published by Elsevier Science B.V. 2002-present.

18. Reviewer for Int. J. Cancer, 2003-present.

19. Reviewer for Biochemical Pharmacology, 2003-present.

20. Reviewer for the Journal of Am. Chem. Soc., 2004-present.

21. Reviewer for European Journal of Medicinal Chemistry, 2004-present.

22. Reviewer for Biochemical Journal, 2004-present.

23. Reviewer for Biological Chemistry, 2005-present.

24. Reviewer for the European Journal of Biochemistry, 2005-present.

25. Reviewer for Cell and Tissue Research, 2006-present.

26. Reviewer for Pathology – Research and Practice, 2008-present.

27. Reviewer for ChemBioChem, 2008-present.

28. Reviewer for Nanomedicine, Future Medicine series, 2009-present.

29. Reviewer for Critical Reviews in Biochemistry & Molecular Biology, 2010-present.

30. Reviewer for ASSAY and Drug Development Technologies, 2010-present.

31. Reviewer for Journal of Enzyme Inhibition and Medicinal Chemistry, 2011-present.

32. Reviewer for Current Molecular Medicine, 2011-

33. Reviewer for Breast Cancer Research and Treatment, 2011-present.

34. Reviewer for International Journal of Medical Sciences, 2011-present.

35. Reviewer for PLoS One, 2011-present

36. Reviewer for Theranostics, 2012- present.

37. Reviewer for Mini-reviews in Medicinal Chemistry, 2012-present.

38. Reviewer for ACS Chemical Neuroscience, 2013-present.

 

Inventions and Patents

1. Q.-X. Sang and Z.J. Sahab “Separation of albumin from protein samples”.

U.S. Patent No.:  US 7,459,542 B2; issued on Dec. 2, 2008

Invention disclosure form entitled “Purification of albumin for therapeutic applications and elimination of albumin from human plasma and other protein mixtures” and a manuscript were submitted on July 16, 2004. Provisional patent application (No. 60/660,384; FSU file: 05-001Sang) was filed on March 10, 2005 as FSU70012.  The FSU invention docket number was 05-001 Sang et al.  Full U.S. patent application was filed on March 2, 2006. Patent was granted and issued on Dec. 2, 2008. U.S. Patent No.:  US 7,459,542 B2.

2. Q.-X. Sang and Z.J. Sahab “Protein separation from a protein mixture”. 

U.S. Patent No. 7585955; issued on September 8, 2009.

USSN 11/366,124 (FSU ref 05-029 Sang; our file FSU 70013.1)

Invention disclosure form entitled “Narrow pI range prefractionation of proteins from crude biological samples prior to 2-DE” and a manuscript were submitted on Oct. 21, 2004. Provisional patent application (No. 60/658,104; FSU file: 05-029Sang) was filed on March 3, 2005 as FSU70013. The FSU invention docket number was 05-029 Sang et al. Full U.S. patent application was filed on March 2, 2006. U.S. Patent No. 7585955, granted and issued on September 8, 2009.

3.  M.A. Schwartz, Y. Jin, D.R. Hurst, and Q.-X. Sang (2005) "Substituted Heterocyclic Mercaptosulfide Inhibitors". Pub. No.:  WO/2005/032541. Pub. Date: April 14, 2005. International Patent Application No.: PCT/US2004/031847. International Filing Date: September 29, 2004.

4. M.A. Schwartz, Y. Jin, and Q.-X. Sang (2013) "Substituted Heterocyclic Mercaptosulfonamide Metalloprotease Inhibitors". United States Patent no. 8,404,866, issued on March 26, 2013. FSU 08-144PCTUS. Pub. No.: WO/2010/028051. Pub. Date: March 11, 2010. International Patent Application No.: PCT US2009/055742. International Filing Date: September 2, 2009. PCT National Filing date, October 7, 2010.  Notice of Allowance issued (patent approved/granted) January 10, 2013. United States Patent no. 8,404,866, issued on March 26, 2013.

5.  Q.-X. Sang, M.A. Schwartz, Y. Jin, and M.D. Roycik (2010) “Method to Reduce Formation of Fat Cells”. Provisional Patent Application No. 61/452,702 was filed on March 15, 2011. FSU invention docket number: 10-140 Sang et al.

6.  I.V. Alabugin, W.-Y. Yang, S. Roy, K. Kaya, and Q.-X. Sang (2011) “Fine-Tuning DNA cleavage: Increased efficiency of double stranded DNA cleavage via structural perturbations in the DNA-cleaving and DNA-binding parts in acetylene amino acid and acetylene dipeptide conjugates”.  Invention Disclosure Form was submitted to FSU, Feb. 10, 2011. A provisional patent entitled “Site-specific cleavage of nucleic acids by photoreactive conjugates” was filed on May 10, 2011.

                        Back to the top

 

 

                   Research Interests

·         Biochemical basis and cellular and molecular mechanisms of human breast and prostate cancer cell progression, invasion, and metastasis; role of matrix metalloproteinases (MMPs) and natural and synthetic inhibitors of MMPs in cancer cell invasion and in angiogenesis (new blood vessel formation); inhibition of cancer cell invasion and metastasis and inhibition of angiogenesis by metalloproteinase inhibitors and development of drug candidates.

·         Molecular mechanisms of blood brain barrier opening, atherosclerosis and restenosis; and role of metalloproteinases and their inhibitors in obesity, stroke, and cardiovascular diseases, and drug development to combat obesity and stroke

·         Molecular modulators and chemical switches of the differentiation and fate determination of human adult bone marrow-derived mesenchymal stem cells; and adult human induced pluripotent stem cells and age-related macular degeneration.

·         Bioanalytical chemistry, proteomics, and biomarker discovery and identification for invasive human breast and prostate cancers and for cardiovascular diseases and stroke. Molecular mechanisms of disease prevention, diagnosis, and treatment.

·         Protein chemistry, enzymology, biochemistry, and molecular biology of new matrix metalloproteinases (MMPs, matrixins), tissue inhibitors of metalloproteinases (TIMPs), and membrane proteinases/receptors, disintegrin and metalloproteinase-like proteins (ADAMs, adamalysins), including discovering and characterizing novel human endometase/matrilysin-2/matrix metalloproteinase-26 and human adamalysin-19/disintegrin and metalloproteinase-19/ADAM19, cDNA cloning, expression, isolation, purification, characterization, sequencing, and chemical modification of proteins.

·         Bio-nano-medicine, biomaterials, nanoscience and nanotechnology in cancer, cardiovascular, stroke, obesity, and diabetes research. Quantum dots and nanoparticles in drug and gene delivery, targeting, and imaging. Test of drug response and drug resistance.

·         Role of focal basal cell disruption in human prostate and focal myoepithelial cell disruption in human breast invasion. Hypotheses on autoimmunity, immunoreactions, and inflammation in cancer cell invasion and malignant transformation.

·         “Mutated cancer stem cell hypothesis”. The plasticity of human cancer cells and stromal cells, epigenetic changes of cancer cells, microenvironmental factors, tumor-stromal interactions in cancer invasion, angiogenesis, progression, and metastasis.

·         Biochemical and pathological activation mechanisms of human metalloproteinases, such as the novel endometase and adamalysin-19.

·         Substrate specificities of MMPs and inhibition mechanisms of MMPs by TIMPs and synthetic inhibitors. Rational drug design and test for the treatment of stroke and cancer.

·         Structure-function relationships of metalloproteinases and their inhibitors, metalloprotease/disintegrin proteins, and extracellular matrix proteins.

·         Bio-mathematical models of cancer and stem cell growth and differentiation, drug response and resistance, and tumor-microenvironmental and epithelial-mesenchymal cell interactions.

·         Computational sequence analysis, homology modeling, and secondary and tertiary structure prediction of MMPs, TIMPs, and other proteins.  Bioinformatics, functional genomics, and proteomics of metalloproteinases and their inhibitors.

·         MicroRNA identification and characterization in human tissues and cells. Role of microRNA and RNAi in cancer, obesity, diabetes, cardiovascular diseases, and stroke.

 

 

News on Sang Lab Research

·         http://www.fsu.edu/news/2011/01/10/bio.markers/

·         http://www.floridabreastcancer.org/research/

·         http://sciencewatch.com/dr/nhp/2008/08novnhp/08novnhpOpde/

·         http://healthystate.org/archives/4770

·         http://www.facebook.com/topic.php?uid=90176037181&topic=9210&post=33946

·         http://fsunews.com/apps/pbcs.dll/article?AID=/20110117/FSVIEW10/110116031

·         http://www.fsu.com/Featured-Stories/An-earlier-start-on-diagnosing-breast-prostate-cancers

·         http://esciencenews.com/articles/2011/01/10/an.earlier.start.diagnosing.breast.prostate.cancers

·         http://www.sciencedaily.com/releases/2011/01/110110121707.htm

·         http://www.fsu.com/Radio-News/Florida-State-investigates-early-signs-of-cancer-Florida-State-honors-Martin-Luther-King-Jr.-s-legacy

·         http://www.news-medical.net/news/20110111/Study-to-identify-early-warning-biomarkers-for-presence-of-breast-and-prostate-cancers.aspx

·         http://www.upi.com/Health_News/2011/01/10/Search-for-cancer-biomarkers-described/UPI-85591294706096/

·         http://www.biomedexperts.com/Profile.bme/1237486/Qing-Xiang_Amy_Sang

·         http://www.newswise.com/articles/an-earlier-start-on-diagnosing-breast-prostate-cancer

·         http://www.newsrx.com/press-releases/12783.html

·         http://www.sciencecodex.com/an_earlier_start_on_diagnosing_breast_prostate_cancers

·         http://www.health.am/cr/more/diagnosing-breast-prostate-cancers/

·         http://newsblaze.com/story/2011011011450800006.wi/topstory.html

·         http://www.pubarticles.com/article-biomarkers-play-central-role-in-cancer-research-1297163624.html

·         http://www.medindia.net/news/Search-for-Breast-Prostate-Cancer-Biomarkers-79358-1.htm

·         http://www.wctv.tv/schools/headlines/An_Earlier_Start_on_Diagnosing_Breast_Prostate_Cancers_113219319.html?storySection=story

·         http://www.azonano.com/news.asp?NewsID=21166